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Cancer is the second leading cause of death worldwide with 9.6 million deaths in 
2019. It is well known that early detection of cancer often leads to a better prognosis. 
However, due to drawbacks associated with current cancer screens (i.e. invasiveness, high 
false positive and negative rates) new or updated early detection methods are needed. 
Chapter one overviews current breast, colon, and prostate detection methods and the 
drawbacks associated with them. Additionally, this chapter presents an alternative 
detection method that utilizes an array of boronic acid functionalized synthetic lectins. We 
describe the development and progression of this array and show the utility of the array 
when discriminating known cancer associated glycans or colon cell lines. Future chapters 
focus on the development of a competitive dual dye screening method for the identification 
of prostate cancer selective synthetic lectins,) transitioning to the use of secreted rather 
than membrane bound glycoproteins extracts and (C) detecting and diagnosing multiple 
cancer types using primary human sources, i.e. tissue and blood samples. 
Chapter 2 reports a dual dye competitive screening method for the identification of 
5 boronic acid functionalized synthetic lectins (SLs) that are selective for prostate 
associated targets with the goal of detecting and staging prostate cancer.  This method uses 
differently labeled normal (RWEP-1) and diseased (PC3) cell membrane extracts in a 
competitive assay to identify SLs that bind to either the cancerous or non-cancerous extract 
but not both.  Subsequent studies examined the efficacy of these new SL hits in an array 
viii 
format to differentiate 6 prostate cell lines.  The SL array was able to, (a) classify the 
prostate cell lines with 83% accuracy, (b) discriminate the same cell lines based on 
metastatic potential (normal/ healthy, cancerous/ lowly metastatic and cancerous/ meta-
static) with 96% classification accuracy, and (c) demonstrate enhanced selectivity for 
prostate versus colon derived cell lines.  Further analysis delineated the contribution from 
each SL in these studies, providing a targeted SL array having potential utility as a cancer 
diagnostic.   
Chapter 3 provide evidence that the same changes in glycan expression occur on 
secreted and membrane bound. Having the ability to detect these changes in glycosylation 
allows for the development of a more liquid biopsy. Additionally, we show that synthetic 
lectins can be used to detect changes in glycosylation and were able to, a) classify the colon 
cell lines with 100% accuracy b) discriminate the same cell lines based on metastatic 
potential (normal, cancerous-lowly metastatic, cancerous-highly metastatic) with 98% 
accuracy and c) through hierarchical clustering we are able to increase the accuracy of the 
analysis. 
Chapter 4 outlines the use of the SL array with multiple cancer types and with 
primary human sources, such as tissue and blood. The SL array was able to discriminate 
breast, colon, and prostate cell line and tissue sample based on disease status with a 96% 
and 88% accuracy. Additionally, the array was able to discriminate blood samples based 
on the presence of breast and prostate cancer with a 90% accuracy. Further studies highlight 
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1.1 COLON CANCER & CURRENT DETECTION METHODS 
Colon cancer is the third most commonly diagnosed cancer in the United States, 
and is the third leading cause of death in both men and women.1 In 2019, there was an 
estimated 101,420 new cases and 51,020 deaths associated with the disease.1 Even with the 
high prevalence, studies suggest that the occurrence of colorectal cancer from 1974 to 
present has been declining.2,3 This reduction has been attributed to an increase in screening 
and access to more effective treatment options.3–6 Early detection and diagnosis has been 
proven to significantly improve patient survival rates and overall quality of life. In fact, 
early-stage colon cancer has a reported 5-year survival rate of 90% whereas the 5-year 
survival rate after metastatic drops to 15%.7 Therefore, continued efforts need to focus on 
developing and improving early detection methods. 
Currently, the “gold standard” for colon cancer screening is the colonoscopy. This 
method allows physicians to view and remove polyps that form on the colon and rectum. 
Polyps are abnormal tissues that are normally harmless but over time can develop into 
cancer. Since there are no symptoms for polyp formation, it is important to have a regular 
colonoscopy so that these growths can be removed at the early stages. While important, 
this procedure is invasive and serious complications such as adverse reactions to the 
sedation, bleeding, diverticulitis, intraperitoneal hemorrhage, and colonic perforation can 
2 
occur.8–11 Additionally, studies have shown that approximately 25% of polyps are missed 
during a colonoscopy.12–15  
Due to the issues mentioned above, the fecal immunochemical test (FIT) was 
created. The method aims to identify blood in the stool caused by bursting polyps. One 
major drawback for this test is that it can only detect polys that are actively bleeding 
thereby, missing newly forming polyps (i.e. neoplasms); resulting in a 58% false negative 
rate.16 Also, there is a  false positive rate of  ~18%, which is caused by blood being in the 
stool from other sources such as stomach ulcers, hemorrhoids, and blood swallowed from 
a mouth or nose injury.17 Since, approximately 1 in 3 people who should undergo screening 
have never done so because of a lack of education about the need for screening,18 cost 
associated with screening and health insurance issues there is  a  need for more cost 
effective and readily available screening methods.  
1.2 PROSTATE CANCER & CURRENT DETECTION METHODS 
Prostate cancer is the most common cancer in men with an estimated 174,650 new 
cases in 2019 and the second leading cause of death with an estimated 31,620 deaths.1  
Currently, the two most common screening methods are the digital rectum exam (DRE) 
and the prostate specific antigen (PSA) blood test. While both methods are commonly used 
there is debate about the validity of these test for asymptomatic men since there are a 
number of risks associated with screening and there is a lack of conclusive evidence 
suggesting that early detection of prostate cancer reduces mortality.19  
For example, the DRE has a malignancy rate of 42.3% for men who are diagnosed 
with an abnormal prostate.20 Therefore, 57.7% of individuals diagnosed with an abnormal 
prostate are undergoing further testing unnecessarily. Studies suggest that this variability 
3 
is caused by differences in training for primary care physicians and differing definitions of 
what constitutes an abnormal result.20 In comparison, the PSA blood test is limited due to 
the lack of specificity, since other disease and conditions, such as benign prostatic 
hyperplasia, urinary tract infection, and prostatitis, can lead to elevated PSA levels.21 
Currently, there is a 75% false positive rate associated with the blood test, meaning that 
only 25% of the men with elevated PSA levels have cancer.22 This can cause the individual 
to undergo and take on unnecessary emotional stress and financial burden. Therefore, more 
accurate detection methods are needed.  
1.3 ABERRANT GLYCOSYLATION 
Protein glycosylation is the most common post-translational modification and is 
involved in a variety of physiological events such as cell-cell and cell-matrix interaction, 
adhesion, and immune response.23 In humans, glycans are attached to proteins through N-
linkages (the glycan attaches to the amide group of an asparagine residue in the consensus 
sequence Asn-X-Ser/Thr) or O-linkages (the glycan attaches to the hydroxyl group of 
serine or threonine).24–26 The glycan environment is dependent on the expression of 
different enzymes (i.e. glycotransferases) and the availability of different precursor 
molecules.27 During the onset and progression of different diseases, such as cancer, 
changes in glycotransferase expression can lead to aberrant glycosylation. This process 
refers to the over-, under-, and neo-expression of glycans (Figure 1.1).28 Consequently, 
cancer cells can experience changes in proliferation, adhesion, motility, angiogenesis and 
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metastasis.27 Significantly, these changes occur during the onset and progression of cancer, 
therefore, identifying changes in glycan expression can be used as a diagnostic predictors 
of morbidity and mortality.29,30   
1.4 BORONIC ACID-DIOL INTERACTIONS 
Initial carbohydrate sensors relied mostly on weak non-covalent interactions (i.e. 
hydrogen bonding and van Der Waals) that performed well in aprotic solvents, but not in 
aqueous solutions, where carbohydrates are found in nature.31 To address this issue, 
boronic acid have been incorporated since boronic acids form covalent yet reversible bonds 
with 1,2- and 1,3-cis diols to form 5- or 6-membered boronate esters.32–35 The covalent 
nature allows for a strong interaction between the boronic acid and the diol, yet the 
reversibility allows for competition between glycans until the sensor reaches equilibrium 
with the most favorable one. 31  The resulting interaction is shown in Figure 1.2. It is 
important to note that the reversibility of this interaction is highly dependent on pH. The 
first equilibrium, K1, shows the formation of the boronate ester from phenylboronic acid 
and a cis-diol. The equilibrium favors the reactants since the boronate ester is typically 
A. B. C. 
Aberrant 
Glycosylation
Figure 1.1-Graphical depiction showing the possible changes to glycan structures after 
aberrant glycosylation. A: shows the over-expression where there is an increase in the 
amount of glycan expressed. B: represents the under-expression where there is a decrease in 
glycan expression. C: illustrates the neo-expression of glycans. During C: a completely new 
glycan replaces the pre-existing one. 
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unstable since the boron has an empty p-orbital.  K2 and K4 show the boronic acid and 
boronate ester, respectively after coordination with a hydroxide ion which fills the empty 
p-orbtial. These equilibrium lie towards the products as the pH increases past the pKa of 
the boronic acid (the pKa of phenyl boronic acid is 8.8).36,37 To favor the formation of the 
ester, a higher pH in aqueous solution is needed to first form the boronate ion. This places 
the boron in a tetrahedral geometry, generating the angle needed to form the cyclic boronate 
ester. At a  physiological pH of 7.3, far below the pKa of most boronic acids, formation of 
the boronate ester is hampered.37,38   
An aminoethyl group was added to the ortho position of the phenylboronic acid. 
Currently, there are two theories to help explain how this addition increases boronate ester 
formation.39 The first suggests that the nitrogen acts as a proton acceptor, thereby aiding in 
the solvolysis of the boron. Alternatively, the nitrogen can also coordinate with the boron, 
causing a weak bond to form (Figure 1.3). In either case, it is important to note that both 
Figure 1.2- The equilibrium between boronic acid and a cis diol lies to the boronate ester 
at higher pHs, where hydroxide coordinates to the boron, causing it to adopt a tetrahedral 
geometry, favoring boronate ester formation. 
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theories force the boron into a tetrahedral geometry, which is favorable for boronate ester 
formation at physiological pH.39  
1.5 SYNTHETIC LECTINS AND CROSS-REACTIVE SENSOR ARRAYS 
Remarkable results have been obtained using natural lectin sensors for cancer 
detection.35,40,41 However, this approach requires prior knowledge of the target analyte and 
in many cases the ideal glycan has not been identified. To complement the use of natural 
lectins, which utilizes a “lock-and-key” approach, we employed an alternative strategy 
known as a Synthetic Lectins (SLs). This design utilizes boronic acid functionalized 
peptides to act as covalent and reversible glycan binders (Figure 1.4).42,43 While natural 
lectins typically exhibit high selectivity for the complementary glycan binding partner, SLs 
most commonly bind glycans cross-reactively.  
Rather than rely on selective sensors, cross-reactive arrays rely on multiple non-
specific sensors, with varying affinities for the target analyte. Multiple receptors are used 
Figure 1.3-The incorporation of an ortho-aminomethyl moiety, which can either increase 
solvolysis of the boron (left equilibrium) or take place of the coordinating hydroxide 
molecule and act as an internal base (right equilibrium), allows boronate ester formation 
in aqueous conditions at neutral pH.  
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to identify small perturbations that form a selective and unique fingerprint pattern specific 
for the analyte(s) (Figure 1.5). This approach mimics the mammalian sense of taste where 
the combination of the responses from a few cross-reactive sensors (e.g., sweet, salty, sour, 
bitter and savory) is used to create a pattern that can be stored in memory to compare with 
future unknown samples to be identified based on the extent of similarity between the 
patterns. 
1.6 IDENTIFYONG SYNTHETIC LECTINS 
Synthetic lectins were identified from a Fixed Position Library (FPL) with the 
general sequence Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-resin where B denotes beta-
alanine, D* denotes diaminobutanoic acid functionalized with 4-formylphenyl boronic 
Figure 1.4 Schematic of a Synthetic Lectin binding a glycoprotein via 
boronic ester linkages. The key elements are labeled, A: peptide 
backbone where Dab represents boronic acid functionalized 
diaminobutanoic acid, B represents beta-alanine, and X represent a 
randomized amino acid, for clarity only one peptide is shown attached 
to the resin bead though millions are present; B: fluorescently labeled 
glycan/glycoprotein; C: covalent yet reversible boronic ester that is 
integral for binding; and D: Secondary interactions between the peptide 
and target glycan (e.g. hydrogen bonding) which helps create the 













acid, and X denotes a random amino acid (Figure 1.4). Library design, optimization, and 
peptide sequencing have been previously described in the work of Lavigne et. al,42,43 but 
will be discussed further in Chapter 2.  
Screening was conducted by incubating the FPL library with fluorescently labeled 
ovalbumin (OVA) and porcine stomach mucin (PSM) (Figure 1.6). OVA and PSM are 
glycoproteins that contain glycans that are known to be over-expressed in colon cancer.44–










Figure 1.6 -Graphical depiction showing the identification of SL hits from 





Figure 1.5-Graphical depiction of a cross reactive sensor array where the 
output for the analyte is the combined results of nine different sensors. 
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significant literature precedence.47–49 A fluorescence microscope fitted with a GFP3 filter 
set (excitation 450-490 nm; emission filter 500-550 nm) was used to identify potential SL 
hits and to take images of the glycoprotein-bound resin.  Beads were identified as hits if 
the resin fluoresced brighter than the other targets. Hits were isolated manually using 
forceps.  The SL hits were sequenced using MS/MS and the sequences can be found in 
Table 1.1. 
1.7 SYNTHETIC LECTINS: SELECTIVITY AND CROSS-REACTIVITY STUDIES 
Hits were subsequently resynthesized and binding selectivity studies were 
completed using OVA, PSM, BSM (bovine submaxillary mucin) and BSA (bovine serum 
albumin).  OVA, PSM, and BSM are all glycoproteins and it is worth noting that PSM and 
BSM contain the same types of glycans but expressed at different levels.42,43 This work 
Table 1.1-Sequences of SL hits 
 
Sequence Screened Against Selectivity 
SL 1 R-G-D*-V-T-F-D*-R-B-B-R-M OVA OVA 
SL 2 R-T-D*-R-F-L-D*-V-B-B-R-M OVA OVA 
SL 3 R-S-D*-V-T-T-D*-R-B-B-R-M OVA PSM 
SL 4 R-R-D*-T-Q-T-D*-Q-B-B-R-M PSM OVA & PSM 
SL 5 R-A-D*-T-R-V-D*-V-B-B-R-M PSM PSM 
SL 6 R-T-D*-N-R-N-D*-F-B-B-R-M PSM - 
SL 7 R-S-D*-Y-F-T-D*-Q-B-B-R-M PSM - 
SL 8 R-T-D*-Y-G-N-D*-N-B-B-R-M PSM - 
SL 9 R-T-D*-Y-Q-V-D*-A-B-B-R-M PSM OVA 
Dashes indicate the SL is cross-reactive rather than selective for a specific 
glycoprotein. 
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showed that while some of the SLs were selective for a particular glycan, several of the 
SLs were cross-reactive, i.e. that they are capable of identifying multiple glycans in an 
unique manner (Figure 1.7). 
1.8 USING SYNTHETIC LECTINS TO DISCRIMINATE CANCER ASSOCIATED 
GLYCANS 
Studies were then completed to test the ability of SLs to act in array by using SL 1, 
3, 4 and 5 to distinguish between 5 similar cancer associated glycans (CAG). Figure 1.8 
shows the structure of the 5 CAG (TF Antigen, Lea,. Lex, sLea, and sLex) used in this 
analysis. These glycans were chosen because they contain saccharides that are commonly 
overexpressed in cancerous cells. To reduce redundancy, SL 2 was not included in the array 
because it showed a similar response to SL 3. SL 6-9 had not been identified at this point 
and therefore were not included in the array. Figure 1.9, which is known as the SL 
Fingerprint, depicts the interaction that each SL has with the different cancer associated 




























OVA BSM PSM BSA
Figure 1.7- Bar graph showing the selectivity studies from SL 1-9. Four different analytes 
were used in this study (OVA, BSM, PSM, and BSA). SL 1, 6, 7, 8, and 9 are cross-
reactive while SL 2 and 4 are selective for OVA, and SL 4 and 5 are selective for PSM. 
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method known as linear discriminant analysis (LDA) was used. This statistical model 
minimizes the separation between points of the same group while maximizing differences 
between points of different groups. Chapter 2 will discuss LDA in more detail but to help 
understand this analysis, LDA attempted to group data associated with the same CAG 
while distances points of differing CAG. Figure 1.10 shows the LDA plot generated from 
the data shown in Figure 1.9. 
TF Antigen Lea Lex
SLea SLex
Figure 1.8-Structures of common CAGs 
















SL1 SL3 SL4 SL5
Figure 1.9- SL Fingerprint showing the response of 5 different 
CAG (TF Antigen, Lea, Lex, sLea and sLex) to the SL array (SL 1, 
3-5) 
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Each shape in Figure 1.10 represents of the array’s response (SL 1, 3-5) to a 
specific CAG. The ellipse surrounding a data set represent the 95% confidence intervals. 
Recall that the LDA attempted to cluster all the points associated with one CAG (ex. TF 
Antigen, blue circles) together while distancing the TF Antigen points from all other CAG. 
Note that tight clustering is observed within the same CAG and minimal overlap occurs 
between the ellipses of different CAG. Additionally, most of the overlap is observed 
between the Lewis antigens and their sialyated form (Lea / sLea and Lex / sLex). To quantify 
this observation, a leave-one-out analysis was used. This technique sequentially removed 
one point from the original data set before creating a new model based on the training set 
from the remaining points. The classification accuracy was determined by the ability of the 
model to properly assign the omitted datapoint to the correct group. Using this analysis, 

























TF Lea sLeaLex sLex
Figure 1.10- Two-dimensional projection for the LDA when 
discriminating the 5 CAGs (4 SLs by 5 CAG, 15 replicates). 
Ellipses represent 95% confidence intervals. 
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1.9 USING SYNTHETIC LECTINS TO DISCRIMINATE COLON CELL LINES 
Since the SL array was able to discriminate between the CAG, the next analysis 
attempted to discriminate colon cell lines based on disease status and metastatic potential. 
When discriminating based on disease status, the cell line was classified as either cancerous 
or healthy / normal and when discriminating based on metastatic potential the cell lines 
were classified as either healthy, cancerous / lowly metastatic, or cancerous / highly 
metastatic. Table 1.2 lists the cell lines used in this experiment. Note that CT26-F1 and 
CT26-FL3 are isogenic cell lines derived from the same parental cell line, CT26.  
Table 1.2-Colon Cell Lines Used In SL Array Studies 
Cell Line Metastatic Potential Cancer Type Origin Species 












Colon  Human 








Colon Liver Mouse 
* Denotes isogenic cell lines derived from the lowly metastatic CT26 cell line. 
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Cells were grown according to ATCC guidelines and a Qiagen membrane 
extraction kit was used to extract the membrane bound proteins from the cells. The samples 
were labeled with FITC and incubated with the SL array. Figure 1.11 shows the LDA plot 
when classifying the 7 colon cell lines based on their response to the SL array. Each point 
represents the response of SL 1, 3-5 to a particular cell line. While this figure does not 
show the 95% confidence intervals it is important to notice that points associated with a 
specific cell lines all cluster together resulting in a leave-one-out classification of 92% 
classification accuracy. Note that points associated with the same metastatic potential 
cluster together which indicates that there is a similarity in phenotypic expression between 








-8 -4 0 4 8
NIH/3T3  (    )
HT29  (    ) HCT116  (    )CT-26  (    )
CT-26-FL3  (   ) LoVo (    )CT-26-F1  (    )
Figure 1.11- The two-dimensional projection for the LDA when 
classifying 7 colon cell lines. The green curved lines highlight the 
separation of healthy, cancerous/non-metastatic, and 
cancerous/metastatic cell types. 
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Jackknife accuracy increases to 97%. Therefore, this analysis shows the utility of using a 
SL array to discriminate colon cell lines based on metastatic potential. 
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CHAPTER 2 
IDENTIFYING SYNTHETIC LECTINS FROM A COMPETITIVE 
SCREEN FOR THE DETECTION OF PROSTATE CANCER
2.1 INTRODUCTION 
We previously attempted to develop a dual-dye screen for the identification of new 
SLs that are selective for a given disease status. Also, we described the identification, 
characterization and utility of a four-SLs array capable of classifying 7 cell lines (1 normal, 
6 colon cancer) with 92% accuracy while exceeding 97% accuracy when classifying based 
on metastatic potential (i.e., stage).42,43  These SLs were identified from a “target-based” 
screen using purified glycoproteins, which were chosen because they contain glycans that 
have been previously correlated with colon cancer.50  It is reasonable to predict that the 
utility and efficacy of the array would be enhanced if the screen used cancer-derived 
targets. Consequently, we focused on identifying SLs that are selective for the detection of 
prostate cancer. We screened our SL library against 2 prostate cell lines extracts, RWPE-1 
and PC3. RWPE-151 is a normal human prostate derived epithelial cell line that was chosen 
to represent a non-cancerous specimen while PC352 is a human prostate adenocarcinoma 
cell line derived from a metastatic site in the bone, chosen as a cancerous sample.  
 Initially, we built on the work of Kodadek et. al53 and Schmitz et. al54 who showed 
that human derived sources could be used as potential ligands when identified from a 
peptide or peptoid library. Kodadek labeled vascular endothelial growth factor receptor 2 
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(VEGFR2) expressing cells with green emitting quantum dots and cells lacking the 
expression of the VEGFR2 receptor with red emitting quantum dots in a two-colored screen 
to identify peptoids that bind the VEGFR2 receptor.53 If a peptoid only bound cells with 
red emitting quantum dots then it was believed that ligand was specific to the VEGFR2 
receptor and that peptoid was isolated as potential VEGFR2 ligands. One positive attribute 
of this method is that it uses receptors on cells that are still in their native conformation. 
However, for these peptoids to bind, the receptor needs to be present on the exterior surface 
of the cell membrane. This presents an issue when detecting sugars rather than receptors, 
since aberrant glycosylation occurs on the exterior as well as the interior of the cell.  
Therefore, in collaboration with Dr. Anna Veldkamp, we attempted to develop a 
dual dye screen for the identification of new SLs that are selective for a given disease status. 
Previously, we described the identification, characterization and utility of a four-SL array 
capable of classifying 7 cell lines (1 normal, 6 colon cancer) with 92% accuracy and 
exceeding 97% accuracy when classifying based on metastatic potential (i.e., stage).42,43   
The focus of the first screen discussed herein was to use cell membrane extracts, to 
determine if SLs could be identified from heterogeneous samples.43 Note that when using 
a single cell line extract, even if a hit binds more effectively during the screen it does not 
indicate that whatever it binds is related to prostate cancer.  Even when the SL is identified 
from PS3 membrane extract the SL could simply be binding ligands associated with the 
prostate which have no direct relevance with cancer.  As such, a second screening approach 
was developed that uses a competitive binding assay between differentially labeled normal 
and diseased cell extracts. While the complexity of this analysis further increases by 
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combining multiple different glycoprotein/protein sources, this competitive assay allows 
us to identify SLs that bind selectively to cancer or non-cancer associated targets. 
2.2 LIBRARY SCREENING USING A SINGLE PROSTATE EXTRACT 
Initially, the bead-based fixed peptide library was synthesized on TentaGel amino 
resin (320 μm; ~6.4 x 104 beads/g) using the split-and-pool method (Figure 2.1).55 This 
method creates a one-bead-one compound (OBOC) library that contains thousands of 
unique peptide sequences. Initially, the resin was split into individual tubes with a different 
amino acid being coupled for each of the tubes.  The resin was then pooled together and 
re-split, so another amino acid could then be coupled. This process was repeated until all 
the random amino acids were coupled. Note that the peptides in this library have the general 










Figure 2.1- The split-and-pool combinatorial 
procedure used to generate peptide libraries. 
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denotes diamino butanoic acid functionalized with 4-formylphenyl boronic acid, and X 
denotes a random amino acid (Figure 1.4). Therefore, the split and pool method needed to 
be repeated five times.  
The amino acids included in the five randomized positions were alanine, glycine, 
valine, leucine, phenylalanine, serine, threonine, tyrosine, asparagine, glutamine, and 
arginine, generating a theoretical diversity of ~2.5 x 105 unique sequences. Cysteine, 
methionine, proline, histidine, glutamic acid, aspartic acid, lysine, tryptophan, and 
isoleucine were excluded as potential random amino acid, X, in the peptides sequence. 
Cysteine and methionine were excluded to avoid issues during cleavage because these 
amino acids contain thiol moieties which are integral in how the peptide is cleaved from 
the resin.  Proline was excluded to avoid adding turns in our peptides. Histidine was 
avoided to allow for more straightforward analysis of side-chain charge. Glutamic and 
aspartic acids were excluded because they have negatively charged side chains. Lysine was 
not used to simplify sidechain deprotection strategies. Tryptophan was excluded because 
SL Sequence Screened 
Against 
Selectivity 
Single Analyte Screen 
SL 10 R-L-D*-A-R-S-D*-G-B-B-R-M PC3  
SL 13 R-T-D*-G-L-A-D*-V-B-B-R-M RWPE-1  
SL 14 R-Y-D*-R-A-S-D*-V-B-B-R-M PC3  
Dual Analyte Screen 
SL 11 R-L-D*-Y-L-T-D*-R-B-B-R-M RWPE-1 / 
PC3 
PC3 




Table 2.1- SL Sequences Identified from the Single and Dual Analyte Screens 
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it has a big and bulky side chain. Isoleucine has the same molecular weight as leucine and 
was avoided to simplify sequencing.  
The samples used for screening the library, membrane bound proteins and 
glycoproteins were extracted from cultured RWPE-1 and PC3 cell lines using a Qiagen 
Membrane Extraction Kit.56 Though working with whole cell extracts removes the targeted 
ligands from their natural environment, i.e., the cell membrane, and results in denaturation; 
compared to whole cells, these samples would be easier to work with in a clinical 
environment.53 Each membrane extract was labelled with a fluorescent dye to detect 
binding with the library members. One potential obstacle is determining if the charge on 
these dyes effects binding since fluorescein is negative while rhodamine is positive. To 
assess the potential impact of fluorophore charge, a portion of the membrane extract from 
each cell lines was fluorescently labeled with rhodamine and fluorescein.  
Screening was carried out by incubating a portion of the SL library with the 
fluroescently labeled membrane extracts. Rather than screening against the entire library 
at once, using a small portion improved the signal-to-noise ratio. A fluorescence 
microscope was used to image the bound SL library. Beads that had a minimum of 1.5 
times the average fluorescence intensity were designated as SL “hits” because they were 
believed to have bound more sample. These results suggest a higher affinity for one or 
multiple analytes from either the PC3 or RWPE-1 samples. The sequences of three SLs 
identified using this approach are shown in Table 2.1. Where SL 10 was identified in a 
screen against fluorescein-tagged PC3 extract (Figure 2.2A), SL 13 was identified from a 
fluorescein-tagged RWPE-1 screen (Figure 2.2B), and SL 14 was identified using 
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rhodamine-tagged PC3 (Figure 2.2C).  These SL hits were isolated from the rest of the 
library and sequenced using Edman Degradation.  
2.3 LIBRARY SCREENING USING A DUAL DYE COMPETITIVE ASSAY 
 To expand on the single analyte screening work, a competitive screening approach 
was developed to help identify SLs exhibiting enhanced selectivity for prostate cancer 
associated targets. Briefly, membrane proteins and glycoproteins were isolated from 
RWPE-1 and PC3. The membrane extracts from RWPE-1 were labeled with rhodamine 
while those from PC3 were labeled with fluorescein (Figure 2.3A). These extracts were 
combined and incubated with a portion of the SL library as described above (Figure 2.3B) 
to establish a competition. Analogous experiments, where we switched the dyes used to 
label each sample were carried out to assess the impact that the charge of the dye had on 
SL binding. Fluorescence microscopy was used to image the bound SL library in the green 
(fluorescein with GFP-3 filter set) and red (rhodamine with DSR filter set) channels. To 
quantify potential SL hits, the normalized fluorescence intensity of a bead in one channel 
relative to the other color channel was determined. A bead was identified as a SL “hit” if 












































































































Figure 2.2- Rhodamine or fluorescein tagged PC3 and RWPE-1 membrane extracts 
binding with SL library. Bar graphs indicate fluorescence channel intensity (rhodamine = 
red, fluorescein = green) for each bead normalized against the average bead intensity 
(outliers rejected at 1.5 IQD) in a particular screening image, i.e. the inset, with the arrow 
identifying the SL hit for: (A) SL 10 using fluorescein-tagged PC3, (B) SL 13 using 
fluorescein-tagged RWPE-1, and (C) SL 14 using rhodamine-tagged PC3 as the analyte. 
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 High fluorescence in only one channel indicated that the SL hit bound a target that 
is expressed only by either the cancerous or non-cancerous sample. While hits that bind 
cancer associated targets are of value, SLs that bind targets from normal samples are also 
of interest because they can assist in distinguishing normal and disease status. Beads that 
fluoresced brightly in both channels were not isolated because these SLs are binding 
something that is prostate associated rather than disease status specific. This dual dye 
screening method resulted in the identification of two SL hits from the same screen, 
Figure 2.3- Schematic showing the identification of new SLs using the dual dye screening 
method. (A) Isolation, purification, and fluorescent labeling of glycoproteins. (B) Mixing 
of cancerous fluorescein-tagged glycoproteins and healthy rhodamine-tagged 
glycoproteins. Mixed glycoproteins are then incubated with the bead based fixed position 
library. 
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referred to as SL 11 and SL 12 (see Table 2.1). SL 11 was brighter in the red channel, as 
shown in Figure 2.4, and therefore is considered selective for the cancerous PC3 cell line. 
SL 12 was brighter in the green channel and therefore considered selective for the healthy 
RWPE-1 cell line. Following sequencing via Edman Degradation, the SLs were re-
synthesized for subsequent studies.  
2.4 VALIDATION OF SL BINDING: DISCRIMINATION OF RWPE-1 AND PC3 
To assess and validate the binding preferences of SL 10-14, we tested the ability of 
these SLs to individually distinguish RWPE-1 and PC3 extracts. We hypothesized that SL 
11 and 12 would more effectively discriminate these cell lines, compared with SL 10, 13, 
and 14, because they were identified from a competitive dual-dye screen. Fluorescence 
intensities were assigned based on the method described above. To account for bead-to-
bead and labelling variability, the fluorescence signal for each SL was normalized against 



















































































Figure 2.4- Dual dye competitive study results. (A) Identification of SL 11 during a FITC 
tagged RWPE-1 and rhodamine PC3 screen. (B) Identification of SL 12 from a 
rhodamine tagged RWPE-1 and FITC PC3 screen. The arrows identify the SL hits. The 
bar graphs show the fluorescent intensities of each of the beads shown in the image. SL 
hits were identified as hits because they fluoresced brighter than the other beads. 
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Initially, T-tests were used to assess the statistical significance of the response from 
each SL to RWPE-1 and PC3 (Table 2.2). The most obvious response differences between 
healthy and diseased samples are exhibited by SL 11 and SL 14, with p-tail values of 
<0.00001, indicating that there is a statistically significant difference in the population 
means. The other 3 SLs afforded p-tail values > 0.2, suggesting that there is little significant 
difference in the response from each SL to these specific normal and diseased prostate cell 
lines.   
To further evaluate the discriminatory ability of the individual SLs and the SL 
array, linear discriminant analysis (LDA) was performed.57 This method attempts to 
minimize variation within each group while maximizing the differences between different 
groups by creating linear combinations of each response pattern and transforming them 
into canonical discriminants. Leave-one-out cross-validation was used to quantify the 
ability of each SL and the array to classify unknowns.58 This technique sequentially 
removed one point from the original data set before creating a new model based on the 
training set from the remaining points. The classification accuracy was determined by the 
ability of the model to properly assign the “left-out” point to the correct group. This method 
allows the response for each analyte to be used as an unknown and the classification 
accuracy to be determined for the entire data set. Classification accuracies for each SL to 
 SL 10 SL 11 SL 12 SL 13 SL 14 
Mean p-value 0.36 <0.001 0.23 0.33 <0.001 
Cross 
validation  
53% 100% 51% 51% 89% 
a N(RWPE-1)/N(PC3)= 18/19 
Table 2.2- T-Test Analysis for the PC3 vs RWPE-1a and leave-one-out 
cross validation accuracy 
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discriminate RWPE-1 and PC3 are given in Table 2.2. The results for the individual SLs 
correlate with the p-tail values, indicating that SL 11 and SL 14 are most effective at 
discriminating these normal and cancerous prostate cell lines, with 100% and 89% 
classification accuracies, respectively. Alternatively, SLs 10, 12 and 13 align more closely 
with the chance accuracy of 50%.  
2.5 VALIDATION OF SL BINDING: DISCRIMINATION OF PROSTATE CELL 
LINES 
Individually, SLs 10, 12, and 13 provide little information to discriminate normal 
(RWPE-1) and cancerous (PC3) cell lines. However, these SLs exhibit cross-reactive 
analyte binding and can therefore be useful when combined into an array.  In this scenario, 
the selectivity of any SL need not be high if the response from each SL is incrementally 
different. By combining these responses, we generate a pattern that is unique for each 
analyte. Additionally, the inclusion of cross-reactive components provides the opportunity 
to evaluate samples and sample classes not previously part of the training set. 
To highlight this adaptability, an SL 10-14 array was combined to discriminate the 
six different human prostate derived epithelial cell lines (RWPE-1, WPE1-NA22, WPE1-
NB14, LNCaP, DU145, PC3).59 Note that WPE1-NA22, WPE1-NB14, LNCaP, and 
DU145 were not included in the initial screen. The response pattern of the SL array to the 
6 different prostate cell lines is shown in Figure 2.5A. Figure 2.5B shows the two-
dimensional projection of the LDA scores (5 SLs by 6 cell lines, N = 116) where the ellipses 
represent the 95% confidence intervals. Each point contains information from the 
fluorescence intensity measurements from each of the 5 different SLs. Note that the points 
corresponding to the same cell line (i.e. color) cluster together, thereby indicating that the 
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model is able to identify the similarities within cell lines. Conversely, minimal overlap 
occurs between the clusters, suggesting that the model can discriminate between cell lines. 
Classification accuracies for this model were evaluated using the leave-one-out 
method.58 Table 2.3 presents the confusion matrix for the analysis. A confusion matrix 
shows the accuracy of a model by identifying (A) which class the different points belong 







































































































































































































































SL 10 SL 11 SL 12 SL 13 SL 14
A
B
Figure 2.5- Classification of 6 prostate cell lines 
using SL 10 through 14. (A) SL Fingerprint 
pattern of the average normalized intensities based 
on the response of the 5 SLs to the 6 cell lines. (B) 
The two-dimensional LDA score plot derived from 
the patterns shown in (A). Ellipses indicate 95% 
confidence level. 
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96 out of 116 samples to afford an 83% overall classification accuracy for the model (with 
a chance accuracy of ~ 17%). Furthermore, the Wilks’ lambda value for this analysis is 
0.012 with a p-tail value <0.001 which indicates that there is a statistically significant 
difference in the population means. Remarkably, even though the SLs had never been 
exposed to the WPE1 cell lines, the array was able to distinguish the isogenic cell lines 
WPE1-NA22 and WPE1-NB14 from RWPE-1 (referred to as the MNU cell lines)59 with 
greater than 96% accuracy. This result serves to demonstrate the ability of cross-reactive 
arrays to learn and respond to new analytes. 
2.6 CANCER CELL DISCRIMINATION: DIRECTED PARTIONING AND DATA 
REDUCTION METHODS 
In the above analysis, substantial overlap was observed between PC3 and LNCaP 
(Figure 2.5B), thereby decreasing the accuracy of the model. Generally, these types of 
misclassifications stem from phenotypic similarities of the cell lines which can be 
important in cancer detection, diagnosis, and prognosis. Therefore, the ability of the array 
to distinguish groups that exhibit similar characteristics was investigated, rather than 
focusing on discrimination of independent cell lines. 






DU145 16 1 0 2 1 0 80 
LNCaP 0 12 6 0 0 1 63 
PC3 0 7 11 0 0 0 61 
RWPE-1 0 0 0 18 1 0 95 
WPE1-NA22 0 0 0 0 0 0 100 
WPE1-NB14 0 1 0 0 20 19 95 
 
Table 2.3- Confusion matrix for the classification of 6 prostate cell lines using SL 10-14. 
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Directed partitioning techniques are commonly used to generate these groups.60 
Typically, this approach relies on statistical methods to reduce the number of classes, such 
as feature selection algorithms or a series of multiple binary classification processes (run 
in parallel, pairwise or hierarchical).61 In contradiction to traditional practices that rely 
solely on statistical models, the current approach relies on the inherent nature of the 
samples to guide the partitioning. These efforts have afforded improved results, we believe 
because logical reasoning is involved.   
For the current analysis, metastatic potential was used as the phenotypic 
characteristic to partition the cell lines into 3 classes: normal/non-cancerous, 
cancerous/low-metastatic and cancerous/high-metastatic. As described above, RWPE-1 
serves as the normal/non-cancerous control, while WPE1-NA22 and WPE1-NB14 
represent a cancerous/low-metastatic phenotype, and LNCaP, DU145 and PC3 denote a 
cancerous/high-metastatic phenotype. Figure 2.6 shows the two-dimensional projection of 
the LDA scores (5 SLs by 6 cell lines partitioned into 3 classes, N = 116, ellipses represent 
the 95% confidence interval). While the variation expressed in Discriminant 1 has no 
apparent correlation with metastatic potential, it is worth noting that the separation 
observed along Discriminant 2 correlates well with disease status (normal or cancerous). 
Significantly, the points corresponding to the same metastatic potential (i.e. color) cluster 
together even though these classes are each composed of different cell lines, thereby 
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indicating that the model is able to identify the phenotypic similarities between cell lines. 
Leave-one-out cross-validation assessed the ability of the SL array to classify samples 
based on their cancer status.58 For this analysis, the array included SL 10-14 and correctly 
classified 111 out of the 116 samples giving a 96% classification accuracy (with a chance 
accuracy of ~ 33%). The Wilks’ lambda value for this analysis is 0.092 with a p-tail value 
<0.00001, indicating a statistically significant difference in the population means. 
Furthermore, the significance of the contribution from the new SLs to discriminate 
samples was evaluated using pair-wise analysis and F-scores obtained from LDA. From 
the pairwise analysis presented in Table 2.2, SL 11 and SL14 are the most effective at 
individually discriminating RWPE-1 and PC3 cell lines. In this narrowly focused analysis, 
note that SL 10, 12 and 13 all had relatively large p-values and the cross-validation 
accuracy was practically identical to the chance accuracy for each SL. F-scores were used 
Figure 2.6- The two-dimensional projection for the 
LDA when discriminating the 6 prostate cell lines 
based on their metastatic potential 
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to statistically compare the contribution from each SL to the overall ability of the array to 
distinguish groups.57 This assessment provides a relative ranking of the importance of each 
SL to predict group membership (Table 2.4). Consistent with the pair-wise results, SL 11 
and SL 14 are the most significant contributors as indicated by the larger F-to-remove 
values.   
Multi-component arrays of the type described herein often include numerous sensor 
elements. To optimize these arrays, a common challenge is to obtain the highest quality 
classification with the fewest sensor inputs. In general, one seeks to minimize the number 
of measurements needed (i.e. the number of sensors), while still retaining reliable and 
reproducible classification. There are numerous ways to visualize the data in these multi-
dimensional analyses by simply including and excluding sensor inputs as desired without 
the need for additional chemical measurements.   
The classification accuracies for various SL combinations were determined based 
on bootstrap analysis as summarized in Table 2.5. When working with relatively small 
sample sizes, bootstrapping is considered to be statistically more robust than leave-one-out 
cross-validation performed on the entire data set.61 In the approach, 25 separate and unique 
data sets were generated, each containing 75 elements, using the Mersenne–Twister 
SL F Scores (Cell Line) 
F Scores (Metastatic 
Potential) 
10 10.54 19.93 
11 125.08 93.35 
12 13.21 14.88 
13 2.75 0.34 
14 23.83 45.94 
 
Table 2.4- F-to-Remove Scores showing the significance of each SL on discriminating 
cell lines based on metastatic potential. 
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random number generator62 in Systat.63 During this sampling, the probability that a data 
point will appear ‘n’ times is close to a Poisson distribution with mean unity. 
Initial analysis using only SL 11 and SL 14 indicated a statistically significant 
decrease in the accuracy of this truncated array compared with the full array (SL 10-14), 
from 80% to 74% classification for the six cell lines and 92% to 86% for the three 
metastatic potential classes. Combining SLs 10, 12 and 13, which contributed the least to 
the full array response, greatly diminished classification accuracies, with the six-cell line 
grouping falling to 53% and the three metastatic potential classes dropping to 62%. Even 
though the individual SLs produced classification accuracies close to chance accuracy, 
when incorporated into array the samples were able to classify the samples based on cell 
line and metastatic potential with 3x and 2x the chance accuracy, respectively.   
Given that the array performed well with all the SLs included, one might predict 
that combining information from either SL 10, 12 or 13 with that from SL 11 and SL 14 
would lead to improved overall classification. Indeed, adding either SL 10 or SL 12 to the 
SL 11/14 array improved overall classification accuracy (Table 2.5). Interestingly, adding 
SL 13 to the SL 11/14 array resulted in decreased overall classification accuracy. We 
 cell line metastatic potential 
SL 10-14 79.9 (±2.1) 92.2 (±1.3) 
SL 11 and 14 74.1 (±2.4) 86.4 (±1.2) 
SL 10, 12, and 13 50.5 (±4.0) 70.0 (±2.8) 
SL 11, 14, and 10 76.2 (±4.1) 90.4 (±1.5) 
SL 11, 14, and 12 75.4 (±3.1) 89.1 (±1.3) 
SL 11, 14, and 13 73.4 (±2.5) 85.7 (±2.4) 
a Average values were calculated from 25 replicates analyses of independently 
randomized samples with N = 75. 
Table 2.5- Bootstrappeda and Percent Classification Accuracies for Six Cell Lines and 
Three-Class Partitioning Based on Metastatic Potential Using Different SL Array 
Combinations 
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hypothesized that this decrease is a result of SL 13 being identified from a single analyte 
screen targeting RWPE-1, the normal prostate cell line. As discussed above, this approach 
produces SLs that could simply bind to prostate-associated glycans and not to targets that 
correlate with the absence or presence of disease. While SL 12 is also selective for RWPE-
1, this SL was identified from a dual-dye competitive binding assay. This approach aims 
to identify SLs that bind targets that are present in either, but not both the cancerous and 
non-cancerous samples. Even though SL 12 does not bind with disease associated targets, 
it does bind target(s) that are unique to normal cells, thereby providing information to help 
discriminate normal and diseased samples. Combining this SL with SL 11 and SL 14 led 
to a modest increase in classification accuracy for the six cell lines. A similar increase was 
observed for discrimination based on the three metastatic potential classes. An analogous, 
though larger, increase was observed when SL 10 was combined with SL 11 and SL 14. 
Note that SL 10 was identified from a single analyte screen using PC3. While there is a 
possibility that SL 10 could, like SL 13, bind target(s) having no correlation with the 
presence or absence of disease, based on this improved classification, it does appear that 
SL 10 binds prostate cancer related target(s). 
2.7 VALIDATION OF SL BINDING: DISCRIMINATION OF 4 COLON CELL LINES 
To assess the selectivity of the SL hits towards prostate cell lines, we tested the 
ability of the array to discriminate 4 colon cell lines: CCD 841 CON a normal human colon 
derived epithelia cell line chosen to represent the non-cancerous phenotype;64 HT2965 and 
HCT11666 are colon derived adenocarcinoma cell lines to represent the cancerous non-
metastatic phenotype; and LoVo,67 an adenocarcinoma cell line derived from the left 
supraclavicular region, chosen to represent the cancerous metastatic cell line. We 
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hypothesized that the SL array would have lower classification accuracy discriminating 
colon cell lines, compared to prostate cell lines. If the classification accuracy is similar 
between the 2 tissue types, this suggests that the SLs are binding non-prostate specific 
targets. 
The protocols outlined above for prostate cell line studies were used when working 
with the 4 colon cell lines. Figure 2.7 shows the two-dimensional LDA projection of the 
LDA scores (5 SLs by 3 potentials, N= 80) where the ellipses represent the 95% confidence 
intervals. Note that in comparison to Figure 2.6, there is more overlap observed between 
colon cell lines of varying metastatic potential then prostate cell lines. Classification 
accuracies were obtained using the leave-one-out method which resulted in the array 
correctly classifying 65 out of the 80 samples to give an 81% classification accuracy (with 
a chance accuracy of 33%). Recall that this SL array correctly classified the prostate cell 
Figure 2.7- Two-dimensional projection for the 
LDA analysis when discriminating the four 
colon cell lines based on their metastatic 
potential. 
34 
lines 96% of the time. These results show a marked increase in classification accuracy, as 
expected, when using prostate rather than colon cell lines. If the array was binding non-
tissue specific cancer associated targets, similar results would be observed for the colon 
and prostate cell lines. 
2.8 CONCLUSION 
The results presented here highlight the effectiveness of the dual-dye competitive 
screening approach. Of the five new SLs described, the most significant was SL 11, which 
was found to be selective for the cancerous cell line PC3. The other SL identified using a 
competitive screen was SL 12, which displayed selectivity for RWPE-1. Noticeably, even 
though SL 12 exhibits selectivity for the normal/non-cancerous prostate cell line it was still 
able to enhance discrimination accuracies for both 6 cell lines and 3 metastatic potential 
classes. The response from SL 14 shows that a single analyte screen can identify hits that 
can effectively discriminate analyte classes. However, the contribution from SLs 10 and 
13 indicate that this approach can identify hits that do not bind disease associated targets. 
Using competitive binding for the identification of hits can enhance selectivity of these 
receptors for specific targets or certain classes of compounds. However, when combined, 
the array can identify analytes (classes) for which it was not initially intended. Specifically, 
these SLs were identified using only RWPE-1 and PC3, yet as an array, these SLs 
effectively discriminated 4 additional cell lines based not only on the cell line identity but 
also based on metastatic potential. Finally, the evidence provided suggests that a smaller 
array can be used to afford classification accuracies like that observed for the full SL 10-
14 array. Thus, there is a significant reduction in the effort and time required to acquire 
35 
and analyze the array response. Overall, integrating these novel hits into an array platform 
serves to improve the utility of the sensor. 
2.9 EXPERIMENTAL METHODS 
General Methods. All chemicals were purchased from Millipore Sigma or Fisher 
Scientific and used without further purification.  TentaGel resin (Cat. No. MB-300-002; 
loading level 0.25-0.3 mmol/g) was purchased from Rapp Polymere.  Cell growth media 
and fetal bovine serum was purchased from VWR International, LLC (West Chester, PA).  
BCA protein quantification kits were purchased from Thermo Scientific.  The SL hits were 
sent to Tufts University Core Facility (Medford, MA) for sequencing via Edman 
Degradation.  
Synthesis of SL Library.  Standard Fmoc / HBTU chemistry was used to attach a 
peptide backbone to the TentaGel resin.  TentaGel was chosen because it is dynamic in 
aqueous and organic solvents, stable in acidic conditions, has a high loading capacity, 
which is important for peptide sequencing, and contains a large number of beads per gram, 
which is important for sequence diversity.  The peptides in this library have the general 
sequence Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-resin where B denotes beta-alanine, D* 
denotes diamino butanoic acid functionalized with 4-formylphenyl boronic acid, and X 
denotes a random amino acid. 250 mg of resin beads were weighed out and soaked in DMF 
for 10 minutes.  8 equivalents of methionine and HBTU were dissolved in 10 mL of 5% 
N-methylmorpholine / DMF.  The solution was left at room temperature for 10 minutes 
before mixing with the resin.  After tumbling for 1 hour, the beads were washed with DMF 
and methanol.  A ninhydrin tests were performed to determine if the amino acids had 
coupled.  The Fmoc group was removed by tumbling the beads in 10 mL 20% piperdine in 
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DMF for 30 minutes.  This process was repeated with arginine and then two β-alanines.  
The random amino acid, X, was coupled to the beads using the split-and-pool method.  
Briefly, the beads were split into 12 different reaction vessels that each contain a different 
activated amino acid.  After coupling, the beads were combined back into one vessel and 
deprotected using 20% piperdine in DMF.  Since the next position is fixed with D*, the 
beads are coupled to the amino acid and deprotected in the same vessel.  The next 6 amino 
acids are coupled depending on the fixed or random position of that amino acid.  Once all 
the amino acids are coupled, the end of the peptide strand is acylated by tumbling the resin 
in 10 mL of 90% dichloromethane, 5% acetic anhydride, and 5% pyridine.  The ivDde 
protecting group of D* was removed by using 10 mL of a 5% hydrazine / DMF solution.   
Incorporation of Phenyl Boronic Acid.  2-Formylphenyl boronic acid (8 eq) was 
dissolved in a mixture of 10% methanol in DMF.  The resin beads, along with activated 
3Ǻ molecular sieves, were added into the solution and tumbled at 37ºC overnight.  NaBH4 
(8eq) was added before and the reaction was left uncapped to allow hydrogen gas to escape 
for 45-minutes.  The resin was left to tumble at 37ºC for 4-hours.  The resin was then 
separated from the molecular sieves, based on density, using dichloromethane.  This was 
followed by washing the beads with copious amounts of DMF and methanol. 
Removal of Acid Labile Groups.  Molecular sieves were removed, and the beads 
were transferred to a Falcon tube.  After the boronic acid moiety was coupled, 10mL of 
95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane (9.5 ml, 250 μL, 
250 μL resp.) was added and the resin was tumbled for 1 hour to deprotect the acid-labile 
protecting groups.  The TFA wash was repeated one more time. The resin was then washed 
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with DMF and methanol.  SLs were tumbled with PBS without glycerol (pH 7.25) twice 
for 10 minutes before future use. 
Library Screen Using Single Analyte Method.  2 mg of library resin was rinsed in 
phosphate buffer saline (PBS) twice and then pre-incubated with 1% BSA in PBS with 
10% glycerol for 15 minutes.  This pre-incubation was to reduce the nonspecific binding 
between the SL and proteins.  The 1% BSA in PBS with 10% glycerol solution was then 
removed from the beads and 1 mL of a 0.0002 mg/mL solution of the fluorescently labeled 
prostate membrane extract in PBS was incubated with the beads for 12 hours at room 
temperature with gentle shaking.  The extract was then removed, and the beads were 
washed three times by adding 1 mL of PBS. Beads were then viewed on a fluorescent 
microscope.  
Library Screen Using Dual Dye Method.  The same protocol outline for the single 
analyte was followed, however, instead of using 1 mL containing 0.0002 mg of both 
analytes to give a total concentration of 0.0004 mg/mL of protein, only 0.0001 mg was use 
of each to make a total concentration of 0.0002 mg/mL. 
Microscopy.  All fluorescent images were taken using a Leica MZ 16F microscope 
equipped with a GFP3 filter (excitation 450-490 nm; emission filter 500-550 nm), DSR 
filter (excitation 510-560 nm; emission filter 590-650 nm), and a QImaging 
MicroPublisher 5.0 RTV digital camera.  Images were analyzed using a MATLAB 
algorithum which provided fluorescent intensities.  
Resynthesis of SL Hits.  500 mg of resin was swelled in 10 mL of DMF for 10 
minutes before being put onto a Protein Technologies Peptide Synthesizer (PS3).  The 
beads were removed from the PS3 after all 12 amino acids has been added.  Once all of the 
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amino acids were couples, the ivDE protecting group on D* was removed by washing the 
beads three times in 5% hydrazine / DMF for 1 hour at room temperature.  Afterwards, the 
phenyl boronic acid was added and the acid laible groups were removed using the protocols 
outlined above. 
MS/MS Analysis.  To verify that the PS3 coupled the correct sequence onto the resin 
MS/MS analysis was used. The peptide was then cleaved from the resin, the beads were 
treated with 50 μl of 40 mg/ml cyanogen bromide (CNBr) in 0.1 M HCl for 16 hours in the 
dark.  The beads were removed from the solution and the excess CNBR, TFA, and water 
were removed under reduced pressure by using an AES1010 SpeedVac system.  The 
cleaved peptides were re-dissolved in 10 μl of 0.1% TFA in water.  A solution of 50:50:0.1 
acetonitrile/water/TFA was saturated with α-cyano-4-hydroxycinniamic acid (CHCA).  On 
a MALDI plate, 1 μl of this matrix containing solution was mixed with 2 μl of the cleaved 
SL solution and dried under ambient conditions.  Samples were then analyzed by MALDI-
TOF/MS and MS/MS techniques. 
Binding Studies with Fluorescent-labeled Membrane Extracts.  Approximately 2 
mg of SL was rinsed in PBS twice and then pre-incubated with 1% BSA in PBS with 10% 
glycerol for 15 minutes.  This pre-incubation was to reduce the nonspecific binding 
between the SL and proteins.  The 1% BSA in PBS with 10% glycerol solution was then 
removed from the beads and 1 mL of a 0.0002 mg/mL solution 45 of the fluorescently 
labeled prostate membrane extract in PBS was incubated with the beads for 6 hours at room 
temperature with gentle shaking.  After incubation, the beads were rinsed with PBS three 
times, imaged with a fluorescent microscope, Leica MZ 16F, and analyzed by Matlab 
R2012a. The output was analyzed by linear discriminant analysis using SYSTAT 11.00.01. 
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Cell Culture.  VWR supplied all the supplements and media needed for cell culture.  
RWPE-1, WPE1- NA22 and WPE1-NB14 cells were grown in Keratinocyte Serum Free 
Media (K-SFM) supplemented with human recombinant epidermal growth factor (rhEGF) 
and bovine pituitary extract (BPR).  PC3, LNCaP, HCT 116 and LoVo cells were grown 
in RPMI 1640 media with 10% feline bovine serum (FBS).  DU145 CCD-841-CON and 
HT29 cells were grown in Eagle’s Minimum Essential Medium Cells supplemented with 
10% v/v of FBS and 1% antibiotics / anti-mycotic were passaged upon 75 % confluence in 
T75 Flasks.  
Fluorescent Labeling of Cell Membrane Extracts.  The Qiagen Plasma Membrane 
Protein Kit was used to extract plasma membrane proteins and glycoproteins. This kit 
isolates all membrane bound proteins not only cancer associated markers. The extract was 
spun into carbonate buffer pH 9.8 and a BCA assay was performed to obtain the 
concentration of the extract.  The amount of protein needed for library screening was added 
to carbonate buffer to a total volume of 600 µL.  Depending on which dye was being used 
to label, 0.07 µmol FITC or rodamine was added and the solution was incubated at 37°C 
and tumbled for 1 hr. Amicon Pro Centrifugal Filter (10 kDa) were used to remove excess 
dye and to concentrate the proteins. 
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CHAPTER 3 
EVALUATING ABERRANT GLYCOSYLATION IN SECRETED AND 
MEMBRANE GLYCOPROTEINS
3.1 INTRODUCTION 
In this chapter, we provide evidence that secreted and membrane bound proteins 
undergo similar glycosylation changes that can be used for the detection of cancer. 
Recently, there has been interest in developing a liquid biopsy for the detection of colon 
cancer due to the invasiveness of colonoscopy and the high false negative rates with fecal 
occult blood tests.68–70 One way to detect changes in cancer status and progression is by 
evaluating changes in the glycome since aberrant glycosylation occurs during the onset and 
progression of cancer.23,28,71 Recently, research has focused on using known biomarkers 
(such as the human carcinoembryonic antigen) in tissue biopsies to stage and monitor colon 
cancer. However, these biomarkers have not been used a diagnostic tool.72,73 If liquid rather 
than tissue biopsies are going to be used, changes to the secreted glycome can be 
monitored. Therefore, this chapter aims to study if secreted and membrane proteins 
undergo similar glycosylation changes and if those changes can be used to detect colon 
cancer.  
Traditionally, natural lectins have been used to identify changes in type and 
expression of glycans.74,75 However, natural lectins require prior knowledge of the target 
and in many cases, the ideal target has yet to be identified. An alternative to this approach 
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is to use a cross-reactive sensor array which incorporates multiple receptors with differing 
affinities for the target analyte(s). As a result, the response from the full array creates a 
unique fingerprint pattern that is specific to that sample.76,77 Therefore, we developed a 
cross-reactive array of synthetic lectins (SLs).42,43 These are polyvalent resin-bound 
receptors composed of boronic acid functionalized peptides designed to bind glycans. 
Rather than looking for a specific glycan, we aimed to look for a phenotypic change 
between normal and diseased states.  
3.2 COMPARING PHENOTYPIC CHANGES IN GLYCOPROTEIN EXTRACTS 
As depicted in Figure 3.1, binding studies were completed in collaboration with 
Dr. Erin Gatrone to investigate how the sample source (i.e., secreted or membrane) 






Figure 3.1-Graphical depiction comparing the 
response of secreted and membrane proteins to 
the SL array. Membrane-bound proteins were 
isolated from cultured cells and secreted proteins 
were isolated from the media of the same 
culture. 
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influenced the response generated by an array of nine SLs (Table 1.1). Four human cell 
lines were used: one normal colon (CCD 841 CoN),78 two lowly metastatic colon cancer 
(HCT116, HT-29)79,80 and one highly metastatic colon cancer (LoVo).81 Membrane 
samples were isolated using a Qiagen Membrane Extraction kit and secreted samples were 
precipitated from the media from the same culture. Note that using these techniques result 
in the isolation of all proteins and glycoproteins from these samples, not only cancer 
associated markers. These heterogeneous samples were fluorescently labeled, incubated 
with the SL array, and imaged using fluorescence microscopy to obtain intensity values for 
each bead-based SL (N ≥ 17 SL per cell line). These values were normalized to the 
maximum intensity within each cell line. 
Using an unguided statistical analysis method, principle component analysis 
(PCA),82 the array response patterns were analyzed. This method attempts to reduce multi-
dimensional data by calculating orthogonal eigenvectors, known as principal components. 
Each component tries to maximize the variance within each data set with the most 
significant characteristic (variance) shown in the lower principal components.83 Figure 3.2 
shows the two-dimensional projection of the resulting factor score (9 SLs by 4 cell lines, 
N =144). In this plot, each point represents the combined response from each of the 
different SLs and ellipses represent the 95% confidence intervals. Note that major overlap 
was observed between the two ellipses suggesting that there is not a statistically significant 
difference in response between the two analytes (i.e. there are similar glycan 
environments). Additionally, the points have almost the same exact clustering pattern 
which validate the hypothesis that a similar glycan environment exists between the secreted 
and membrane extracts.  
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Linear discriminant analysis (LDA) was used to determine if the response of the 
two extracts was the same. This guided analysis technique creates linear combinations of 
each response pattern and calculate canonical discriminants to minimizes the variations 
within an extract while maximizing the differences between extracts.84  Fluorescence 
intensity datawas obtained using the previously described procedure and the values were 
normalized to the brightest bead from each cell lines. Figure 3.3 shows the two-
dimensional projection of the LDA scores (9 SLs by 4 cell line, N=72) for both samples. 
Note that these plots look almost indistinguishable with the only significant overlap 
observed in both plots being between the two lowly metastatic cell lines, HCT 116 and 
HT29. This indicates that a very similar glycan environment exists between the membrane 
and secreted samples.  








































































Figure 3.2-Two-dimensional projection of the 
PCA factor scores from analyzing the array 
response from membrane and secreted samples 
(9 SLs by 4 cell lines, N =144). 
44 
To quantify the accuracy of this approach, the leave-one-out cross validation was used. 
Based on the analysis, the model correctly classified 70 out of 72 samples resulting in a 
97% classification accuracy and 69 out of the 72 samples resulting in a 96% accuracy (with 
a chance accuracy of 25% for both analyses). Significantly, for both analyses the only 
misclassifications resulted from misclassifying the HCT 116 and HT29 as the other cell 
line. These results highlight the similarity in response between both extracts within 
statistical variability.  
In the above analysis, the overlap observed in Figure 3.3 stems from phenotypic 
similarities between two cell lines (i.e. HCT 116 and HT29), specifically the metastatic 
potential of the cell line. Therefore, we explored the ability of the array to distinguish 
between groups with similar phenotypic characteristics (i.e. metastatic potential). Figure 
3.4 shows the two-dimensional projection of the LDA scores (9 SLs by 3 potentials, N=72) 
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Figure 3.3- Two-dimensional projection for the LDA when classifying the 4 colon cell 
lines from (A) the membrane and (B) secreted samples (9 SLs by 4 cell lines, N =72). 
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for both samples. Note that there is no overlap between the different groupings thereby 
suggesting that the overlap between the HCT 116 and HT29 cell lines is caused by 
similarities in metastatic potential. Additionally, the response of both membrane and 
secreted samples results in an almost identical plot further suggesting a similarity in glycan 
environments. Leave-one-out cross validation resulted in all 72 points correctly being 
classified, a 100% classification accuracy for both samples (with a chance accuracy of 
33.3%).  
3.3 TRANSITIONING TO A LIQUID BIOPSY: USING DIRECTED PARTIONING 
TO AID IN DATA ANALYSIS 
From a clinical perspective, there are three stages in cancer detection. The first stage 
focuses on detecting the presence or absence of disease. Afterwards, the focus shifts to 
staging the disease and finally sub-typing the specific type of cancer. Therefore, we tested 
Canonical Scores Plot

















































































Figure 3.4-Two-dimensional projection for the LDA when discriminating the 4 colon 
cell lines based on metastatic potential from (A) the membrane and (B) secreted 
samples (9 SLs by 4 potentials, N =72 each). 
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the ability of the array to as a cancer diagnosis with the secreted samples by using 
hierarchical clustering to complete a series of 2-class groupings.85  The same studies were 
completed with the membrane samples and are included in the Figure 3.5. Initially, we 















































































Figure 3.5-Two-dimensional depictions of the 
LDA results when discriminating membrane 
extracts from 4 colon cell lines based on (A) 
status, (B) metastatic potential, and (C) cell type. 
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(HCT 116, HT29, LoVo) from the normal sample (CCD 841 CoN). Figure 3.6 shows the 
box and whisker plot of the single discriminant from the LDA. Since no overlap was 
observed between the two plots and the p-value for this analysis is <0.0001, this indicates 
that there is a statistical difference in the population means. Leave-one-out cross validation 










































Figure 3.6-Two-dimensional depictions of the 
LDA results when discriminating secreted 
extracts from 4 colon cell lines based on (A) 
status, (B) metastatic potential, and (C) cell type. 
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The second analysis focused on the array acting as a staging tool. The lowly 
metastatic cell lines (HCT 116 and HT29) were chosen to represent the early stages of 
colon cancer and the highly metastatic cell line (LoVo) represent the later stages of the 
disease. Figure 3.6 shows the box and whisker plot of the single discriminant derived from 
the model created using LDA. The leave-one-out cross validation resulted in 52 out of the 
53 samples being classified accurately, a 98% accuracy and a p-tail value of <0.0001. 
Finally, the lowly metastatic cell lines were classified according to cell line to determine if 
this diagnostic method could identify specific cancer types, e.g., sub-type (Figure 3.6). In 
this analysis, 35 out of the 36 samples were correctly classified, resulting in 97% accuracy 
and a p-tail value of <0.0001. In the original analysis where the four cell lines were 
simultaneously analyzed (Figure 3.3), the overall classification was lower than that 





































































































































 841 CoN LoVo CCD 841 CoN* L o*
Figure 3.7- Two-dimensional projection of the 
fact r scores when discriminating CCD 841 CoN 
and LoVo before and after treatment with a 
sialidase enzyme. * denotes that the sialic acid 
was cleaved from that samples (9 SLs by 2 
sialidase treatments and 2 cell lines, N =112). 
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observed using this hierarchical approach. Specifically, HCT 116 classification accuracy 
was improved from 88% to 93% while HT29 remained constant at 94%. These results 
suggest that this approach can be useful as a diagnostic tool with secreted samples.  
3.4 GLYCAN BINDING STUDIES 
Given this success and our interest in binding glycans, we decided to investigate 
whether glycans are important in binding. Previously, we have shown that once all glycans 
were cleaved from purified glycoproteins no observed binding occurred.86 Similarly, 
glycan competition studies were used to help identify particular sugars that were influential 
in SL binding.43 While these experiments produced compelling results, we want to evaluate 
the effect on SL binding by removing a known cancer associated glycan. Specifically, 
binding studies were completed using the normal (CCD 841 CoN) and highly metastatic 
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LoVo without sialic acid
LoVo with sialic acid
CONA without sialic acid
CONA with sialic acid 
Figure 3.8- Two-dimensional projection of the LDA scores when discriminating CCD 
841 CoN and LoVo before and after treatment with a sialidase enzyme. * denotes that the 
sialic acid was cleaved from that samples (9 SLs by 2 sialidase treatments and 2 cell 
lines, N =112). 
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(LoVo) colon cell lines, before and after they were treated with a sialidase enzyme. This 
enzyme selectively cleaves sialic acid, a glycan known to be over-expressed in colon 
cancer.73,87,88 
Figure 3.7 shows the two-dimensional projection of the PCA factor scores. Note 
that no overlap was observed between the healthy and cancerous cell lines with sialic acid. 
Additionally, the one-way ANOVA shows statistically significant differences between 
group means (F(1,62) =524.6 , p =<0.0001). In comparison, after using the sialidase 
enzyme major overlap was observed between the ellipses. Also the one-way ANOVA 
shows that there is a similarity in group means (F(1,46) =4.44 , p =0.04). Similar results 
can be observed in the LDA output (Figure 3.8).  
3.5 CONCLUSION 
In summary, analysis of secreted and membrane bound protein shows that similar 
glycan environments exist during the onset and throughout the progression of cancer. These 
similarities may be caused by analogous changes in glycotransferases. While more 
investigation is needed to understand the detailed mechanism behind aberrant 
glycosylation, current research suggests that changes in glycosylation are mediated by the 
expression, localization, and activity of glycotransferases.89–91 In normal / healthy cells, 
glycosylation occurs in the secretory pathway, which is comprised of the endoplasmic 
reticulum (ER) and Golgi apparatus, since glycotransferases are located in these two 
organelles. In tumor cells, the pH of the Golgi increases which leads to the mislocalization 
of glycotransferases into the cytosol.89 Thereby allowing the glycotransferases to 
irregularly interact with proteins destined to be secreted or bound to the membrane. 
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Additionally, a similar array response may be observed because we are detecting 
changes in glycan expression rather than the most abundant glycans. Even minor changes 
in glycan expression can result in major changes in the biological activity of the cell.90 In 
our analysis, we attempted to identify the most consequential changes that occurred 
between the normal and cancerous cell lines. Therefore, our SLs are not necessarily 
identifying the most abundant glycan rather they are identifying the glycans that cause the 
most significant change.  
Also, in the chapter we highlighted the ability to use secreted proteins in a liquid 
biopsy. Through hierarchical clustering we were able to not only discriminate secretions 
from cancerous and normal cell lines with 100% accuracy, but we were further able to 
classify cell lines based on metastatic potential with 98% and by cell type with 95% 
accuracy. Note that for all of these analyses the secreted and membrane bound proteins had 
a similar response further suggesting that a similar glycan environment exists. Finally, we 
provided evidence to support the hypothesis that our SLs are binding glycans. Removing 
the known cancer associated glycan, sialic acid, results in a similar array response for the 
healthy CCD 841 CoN cell line and the cancerous LoVo cell line. Thereby suggesting that 
our SLs are binding glycans rather than another portion of the protein.  
3.6 FUTURE WORK  
 This work suggests the remarkable result that secreted and membrane bound 
proteins have very similar glycosylation patterns. However, to verify this observation, 
future work will focus on identifying the specific glycans that are present on secreted and 
membrane bound proteins. Commonly, antibodies or lectins have been used to determine 
which glycans are present. However, antibodies traditionally recognize protein sequences 
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rather than glycans and lectins selectively bind specific sugars. Additionally, previous 
knowledge about what is being bound is required prior to doing the analyses. Therefore, if 
this method does not work, mass spectrometry in conjunction with glycan databases can 
be used to identify the specific glycans that are present. This is an alternative option 
because of the challenges associated with understanding the results if you are not 
experienced in glycomics.   
3.7 EXPERIMENTAL METHODS 
General Methods. All chemicals were purchased from Millipore Sigma or Thermo 
Fisher Scientific and used without further purification.  TentaGel resin (Cat. No. MB-300-
002; loading level 0.25-0.3 mmol/g) was purchased from Rapp Polymere.  Cell growth 
media and fetal bovine serum was purchased from VWR International, LLC (West Chester, 
PA).  BCA protein quantification kits were purchased from Thermo Fisher Scientific.  
Amicon 3kDa centrifuge tubes and the Sialic Acid Quantitation Kit were purchased from 
Millipore Sigma.  
Synthesis of SL Library.  Standard Fmoc / HBTU chemistry was used to attach a 
peptide backbone to the TentaGel resin. The peptides in this library have the general 
sequence Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-resin where B denotes beta-alanine, D* 
denotes diamino butanoic acid functionalized with 4-formylphenyl boronic acid, and X 
denotes a random amino acid.  250 mg of resin beads were weighed out and soaked in DMF 
for 10 minutes.  8 equivalents of methionine and HBTU were dissolved in 10 mL of 5% 
N-methylmorpholine / DMF.  The solution was left at room temperature for 10 minutes 
before mixing with the resin.  After tumbling for 1 hour, the beads were washed with DMF 
and methanol.  A ninhydrin tests were performed to determine if the amino acids had 
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coupled.  The Fmoc group was removed by tumbling the beads in 10 mL 20% piperdine in 
DMF for 30 minutes.  This process was repeated with arginine and then two β-alanines.  
The random amino acid, X, was coupled to the beads using the split-and-pool method.  
Briefly, the beads were split into 12 different reaction vessels that each contain a different 
activated amino acid.  After coupling, the beads were combined back into one vessel and 
deprotected using 20% piperdine in DMF.  Since the next position is fixed with D*, the 
beads are coupled to the amino acid and deprotected in the same vessel.  The next 6 amino 
acids are coupled depending on the fixed or random position of that amino acid.  Once all 
the amino acids were coupled, the end of the peptide strand is acylated by tumbling the 
resin in 10 mL of 90% dichloromethane, 5% acetic anhydride, and 5% pyridine.  The ivDde 
protecting group of D* was removed by using 10 mL of a 5% hydrazine / DMF solution.   
Incorporation of Phenyl Boronic Acid.  2-Formylphenyl boronic acid (8eq) was 
dissolved in a mixture of 10% methanol in DMF.  The resin beads, along with activated 
3Ǻ molecular sieves, were added into the solution and tumbled at 37ºC overnight.  NaBH4 
(8 eq) was added before and the reaction was left uncapped to allow H2 gas to escape for 
45-minutes.  The resin was left to tumble at 37ºC for 4-hours.  The resin was then separated 
from the molecular sieves, based on density, using dichloromethane.  This was followed 
by washing the beads with copious amounts of DMF and methanol. 
MS/MS Analysis.  To verify that the PS3 coupled the correct sequence onto the resin 
MS/MS analysis was used. The peptide was then cleaved from the resin, the beads were 
treated with 50 μl of 40 mg/ml cyanogen bromide (CNBr) in 0.1 M HCl for 16 hours in the 
dark.  The beads were removed from the solution and the excess CNBR, TFA, and water 
were removed under reduced pressure by using an AES1010 SpeedVac system.  The 
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cleaved peptides were re-dissolved in 10 μl of 0.1% TFA in water.  A solution of 50:50:0.1 
acetonitrile/water/TFA was saturated with α-cyano-4-hydroxycinniamic acid (CHCA).  On 
a MALDI plate, 1 μl of this matrix containing solution was mixed with 2 μl of the cleaved 
SL solution and dried under ambient conditions. Samples were then analyzed by MALDI-
TOF/MS and MS/MS techniques. 
Removal of Acid Laible Groups. Molecular sieves were removed, and the beads 
were transferred to a Flacon tube.  After the boronic acid moiety was coupled, 10mL of 
95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane (9.5 ml, 250 μL, 
250 μL resp.) was added and the resin was tumbled for 1 hour to deprotect the acid-labile 
protecting groups.  The TFA wash was repeated one more time.  The resin was then washed 
with DMF and methanol.  SLs were tumbled with PBS without glycerol (pH 7.25) twice 
for 10 minutes before future use. 
Microscopy. All fluorescent images were taken using a Leica MZ 16F microscope 
equipped with a GFP3 filter (excitation 450-490 nm; emission filter 500-550 nm), DSR 
filter (excitation 510-560 nm; emission filter 590-650 nm), and a QImaging 
MicroPublisher 5.0 RTV digital camera.  Images were analyzed using a MATLAB 
algorithum which provided fluorescent intensities.  
Resynthesis of SL Hits. 500 mg of resin was swelled in 10 mL of DMF for 10 minutes 
before being put onto a Protein Technologies Peptide Synthesizer (PS3).  The beads were 
removed from the PS3 after all 12 amino acids has been added.  Once all of the amino acids 
were couples, the ivDE protecting group on D* was removed by washing the beads three 
times in 5% hydrazine / DMF for 1 hour at room temperature.  Afterwards, the phenyl 
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boronic acid was added and the acid laible groups were removed using the protocols 
outlined above. 
Binding Studies with Fluorescent-labeled Membrane Extracts. Approximately 2 
mg of SL was rinsed in PBS twice and then pre-incubated with 1% BSA in PBS with 10% 
glycerol for 15 minutes. This pre-incubation was to reduce the nonspecific binding between 
the SL and proteins.  The 1% BSA in PBS with 10% glycerol solution was then removed 
from the beads and 1 mL of a 0.0002 mg/mL solution 45 of the fluorescently labeled colon 
membrane extract in PBS was incubated with the beads for 6 hours at room temperature 
with gentle shaking.  After incubation, the beads were rinsed with PBS three times, imaged 
with a fluorescent microscope, Leica MZ 16F, and analyzed by Matlab R2012a.  The output 
was analyzed by linear discriminant analysis using SYSTAT 11.00.01. 
Cell Culture. CCD 841 CoN cells were grown in Minimum Essential Media 
(MEM). HCT 116 and LoVo were cultured in RPMI-1640 and HT29 used Dulbecco’s 
Modified Eagle Media (DMEM). All cells were supplemented with 10% v/v of FBS and 
1% antibiotics / anti-mycotic and passaged upon 75 % confluence in T75 Flasks.  
Extracting Membrane Samples. The Qiagen Plasma Membrane Protein Kit was used to 
extract plasma membrane proteins and glycoproteins. This kit isolates all membrane bound 
proteins not only cancer associated markers. The extract was spun into carbonate buffer 
pH 9.8 and a BCA assay was performed to obtain the concentration of the extract. 
Extracting Secreted Samples. After cells reached 75% confluence, they were 
starved for 48 hours. The media was transferred into an Amicon 3kDa centrifuge tube and 
centrifuged until approximately 1500 µL of media remained in the filter. Then 15 mL of 
PBS was added to the filter and spun to remove the remaining media. The remaining protein 
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dissolved in PBS was transferred to a 50 mL Falcon tube before adding 4 eq v/v of -30⁰ 
acetone. The solution was stored in a -30⁰ overnight.  The sample was centrifuged, and the 
acetone was removed using a pipette. The tube was left uncovered in the hood for 30 mins 
to remove any remaining acetone. A BCA assay was preformed to obtain the contraction 
of the protein sample. 
Fluorescently Labeling Protein Samples. 28 µg of FITC (71.9 nmol) in DMF was 
added to the isolated membrane and secreted protein samples. The solution was incubated 
at 37°C and tumbled for 1 hr before being transferred to an Amicon Pro Centrifugal Filter 
(10 kDa) to remove excess dye and to concentrate the proteins.  
Cleavage of Sialic Acid from Colon Cell Lines. A Sialic Acid Quantitation Kit was 
used to quantify the total sialic acid concentration in the CCD 841 CoN and LoVo cell 
lines. This kits also cleaves variants of sialic acid such as N-glycolyl or O-acylneuraminic 
acid. After sialic acid quantitation was completed, each tube contained intact protein 
samples from each cell line in Tris reaction buffer along with total free sialic acid residues, 
1µM quantity of each sialidase, aldolase and dehydrogenase 148 enzymes. To get rid of 
the total free sialic acid from the leftover intact protein sample and consequently tag the 
leftover proteins, we added 10µL of FITC dissolved in 10:1 ratio of PBS: DMF. The protein 
solution was covered and tumbled at 37°C for 1-hour. Later, the protein solution was 
centrifuged at 4000 RPM using Amicon® 10-KDa centrifuge tubes. The buffer was 
exchanged from Tris buffer (pH 7.5) to PBS (pH 7.3) using the buffer exchange tube, by 
addition of 1.5 mL of PBS. The leftover intact-labeled protein was collected and a BCA 
assay was run before using the labeled protein for further experimentation. 
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Binding Studies with Fluorescent-labeled Colon Cell Lines Before and After 
Sialidase. The same protocol outlined for the binding studies with fluorescent-labeled 
membrane extracts was followed except the samples obtained from the cleavage of sialic 




USING A SL ARRAY WITH MULTIPLE HUMAN DERIVED SAMPLES
4.1 INTRODUCTION 
As previously discussed, aberrant glycosylation of membrane and secreted 
glycoproteins is a hallmark of cancer.30,92 It is widely believed that different types of cancer 
and stages of cancer produce distinctive glycosylation patterns that present a unique 
opportunity for determining the malignancy and the metastatic potential of a sample.23,27 
One major goal for this project was to utilize the SL array to differentiate the unique 
glycosylation patterns, and thereby develop the SL array into a screening tool.  
Previous work focused on using the SL array to detect and stage cancer using 
samples from a single tissue type. As described in Chapter 1, an array composed of SL 1, 
3-5, was able to discriminate 7 colon cell lines based on metastatic potential with 97% 
accuracy. However, if the SL array is going to be used as a liquid biopsy, as discussed in 
Chapter 3, then the array needs to be able to detect multiple cancer types from a patient 
sample, e.g. blood. Therefore, this chapter presents our first attempts to detect and stage 
cancer from cell lines derived from different tissue types (i.e. breast, colon, and prostate 
cell lines). Consequent work focused on using the SL array to screen and diagnosis cancer 
using primary human derived samples, such as tissue and blood. To illustrate these 
objectives, various analyses were completed using the same dataset but with different 
parameters. When using multi-dimensional analyses, data can be visualized numerous 
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ways, without the need for additional chemical experiments, by simply including and 
excluding sensors inputs as well as varying perspectives. 
4.2 EVALUATING BREAT, COLON, AND PROSTATE CELL LINES USING 
MULTIDIMENSIONAL ANALYSIS 
Binding studies, outlined in Chapter 2, were completed to investigate the capability 
of the array to discriminate 15 different cell lines based on tissue type (Table 4.1, Table 
4.2, and Table 4.3). Membrane bound proteins and glycoprotein samples were extracted 
using a Qiagen Membrane Extraction Kit before being fluorescently labeled with FITC. 
Fluorescence microscopy was used to obtain an emission intensity for each bead (N =277). 
These values were normalized to the maximum intensity within each tissue type.  
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As mentioned in Chapter 3, initial analysis focused on identifying the presence or 
absence of disease. When analyzing this data set, quadratic discriminant analysis (QDA) 










HCT11680 Cancerous Lowly Metastatic 
HT2981 Cancerous Lowly Metastatic 
LoVo81 Cancerous Highly Metastatic 
 






Prostate Cell Line 
RWPE-1a 51 Healthy Healthy 
WPE1-NA22a 
103 
Cancerous Lowly Metastatic 
WPE1-NB14a 
104 
Cancerous Lowly Metastatic 
DU145105 Cancerous Highly Metastatic 
PC352 Cancerous Highly Metastatic 
LNCaP106 Cancerous Highly Metastatic 
a. Isogenic cell lines derived. WPE1 cell lines are 
derived from RWPE-1. 
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was used because LDA requires an assumption of equal variance-covariance of the 
classes.93 Specifically, variance refers to the spread of a data set around its mean value, 
which in the context of this analysis refers to the variation between points of the same 
group (i.e. points of the same status). While covariance refers to the measure of the 
directional relationship between two random variables or for this analysis the variation 
between points of different types (i.e. healthy verses cancerous points).94 Since this data 
set is looking at multiple tissue types, we could not assume equal variance-covariance since 
the response of the array may be more effected by one group variable then another (ie. 
tissue type verses disease status). If LDA were used and there is a substantial difference 
between the inputs, the inputs tend to be assigned to the class where variability is greater.  
Therefore, QDA was used because it accounts for the heterogeneity of classes and therefore 
will result in a more representative model.  
Figure 4.1 shows the projection of the QDA analysis when discriminating the 15 
cell lines using the SL array (SL 1-9) based on disease status (N=277). While some overlap 
is observed between the plots, it is important to note that there is no overlap between the 
boxes indicating that there is a difference between the interquartile range, the middle half 
of the data set, for the two groups. Additionally, having a p-value of <0.0001 for this 
analysis suggests that there is a statistically significant difference between the group means. 
Leave-one-out cross validation results in 266 out of the 277 samples being correctly 
classified, or a 96% classification accuracy.  
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The following analysis differs from Chapter 3 because we had to consider what 
tissue was affected before staging and sub-typing. Figure 4.2 shows the two-dimensional 
projection of the QDA analysis when discriminating the cancerous cell lines based on tissue 
type. Note that only the cancerous samples were used because a patient that tested negative 
for cancer would not undergo further testing. Minimal overlap is observed between the 
ellipses suggesting a difference in response between the tissue types. Additionally, a p-
value of <0.0001 for this analysis suggests that there is a statistically significant difference 
in group means. Leave-one-out cross validation results in 213 out of 218 samples being 
correctly classified, or a 98% accuracy, with all the breast and prostate samples being 















































Figure 4.1- Depiction of the QDA results when discriminating 15 cell lines 
extracts based on disease status (9 SLs by 2 states, N = 277). The 
italicized numbers indicate the number of samples that were correctly 
classified out of the total sample population in the leave-one-out analysis.  
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The final two analyses attempted to stage and subtype the different cancer types. 
Figure 4.3 show a depiction of the QDA results for the breast, colon, and prostate cell lines 
when discriminating based on metastatic potential. For this analysis, the highly metastatic 
cell lines represent the later more aggressive stages while the lowly metastatic cell lines 
represent the earlier stages of the disease. No overlap is observed between the box-and-
whisker plots for all three tissue types and each analysis results in a p-value of <0.0001 
which suggests that there is a statistically significant difference between the group means. 
Finally, leave-one-out cross validation results in all samples being correctly classified or a 
100% classification accuracy.   
Canonical Scores Plot
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Figure 4.2- Two-dimensional depiction of the QDA results when discriminating the 
cancerous cell lines extracts based on tissue type (9 SLs by 3 tissue types, N = 218). 
Ellipses represent 95% confidence intervals. 
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Figure 4.4 shows the projection of the QDA results when discriminating the lowly 
metastatic cell lines based on cell type. Figure 4.5 shows the two-dimensional projection 
of the QDA shows when discriminating highly metastatic cell lines based on cell type. 
These analyses aimed to show the arrays’ ability to subtype different cancers.  Minimal to 
no overlap is observed between the plots and a p-value of <0.0001, for all three analyses, 
indicates that there is a statistically significant difference in group means. Leave-one-out 
cross validation results in all samples being correctly classified, or a 100% classification 
accuracy.  
The results described above demonstrate the ability of the SL array to act as a cancer 
detection and staging method. Initial analysis showed the ability of the array to discriminate 
the samples based on disease status with a 96% accuracy. Additional work highlighted the 
array’s ability to identify the effected tissue with a 98% accuracy. Thus, detecting cancer 
along with identifying the tissue associated with the disease (i.e. breast, colon, and prostate) 
















































Figure 4.3- Depictions of the QDA results when discriminating breast, colon, and 
prostate cell lines extracts based on metastatic potential (9 SLs by 2 potentials). The 
italicized numbers indicate the number of samples that were correctly classified out of the 
total sample population in the leave-one-out analysis. 
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tissue type, the individual now knows that they should go for further testing to identify the 
site of the malignancy.  Furthermore, the response generated from the SL array was able to 












































Figure 4.5- Depictions of the QDA results 
when discriminating highly metastatic 
prostate cell lines extracts based on cell type 
(9 SLs by 3 cell types). The italicized 
numbers indicate the number of samples that 
were correctly classified out of the total 
sample population in the leave-one-out 
analysis. 
Breast
















































Figure 4.4- Depictions of the QDA results when discriminating lowly metastatic breast, 
colon, and prostate cell lines extracts based on cell type (9 SLs by 2 or 3 cell types). The 
italicized numbers indicate the number of samples that were correctly classified out of the 
total sample population in the leave-one-out analysis. 
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between isogenic cell lines, such as MCF10A and MCF7 as well as RWPE-1, WPE1-NB14 
and WPE1-NA22 with a 100% accuracy, a result that is difficult to achieve with a classic 
“lock-and key” sensing method.83 Based on these initial cell line investigations, the SL 
array is capable of detecting and staging cancer from samples of varying tissue origin.  
4.3 EVALUATING BREAST, COLON, AND PROSTATE TISSUE SAMPLES USING 
MULTI-DIMENSIONAL ANALYSIS 
While the above analyses produced exceptional results, cell lines do not embody 
the complexity of a tumor. To examine the ability of the SL array to work with clinical 
specimens, 30 matched tissue samples (4 breast, 22 colon, and 4 prostate) were used. Note 
that a matched sample refers to two samples taken from adjacent sites of the same tissue 
except one of the samples is classified as normal / healthy and the other cancerous by 
histology. The tissue samples were frozen in liquid nitrogen and pulverized using a mortar 
and pestle. Membrane proteins were extracted from the resulting powder using a Qiagen 
membrane extraction kit, labeled with FITC, and incubated with the SL array. Fluorescence 
intensity data were collected for each sample using fluorescence microscopy. 
Figure 4.6 shows the two-dimensional projection of the QDA results when 
discriminating 30 tissue samples based on disease status in conjunction with tissue type (9 
SLs by 6 classes, N =1009). Note that these results were a combination of multiple 
technical replicates. We combined these analyses to test if subsequent steps could be 
combined and still achieve a similar response. Leave-one-out cross validation results in 
884 out of 1009 samples being correctly classified, or an 88% accuracy. While overlap is 
observed between ellipses, it frequently occurs between samples of the same tissue type, 
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which may be a result of using isogenic samples. With multi-dimensional analyses, there 
are numerous ways to visualize data by simply including and excluding sensor inputs 
without the need for additional chemical experiments. By re-analyzing the data set with a 
different set of parameters information can be gathered from different perspectives. Figure 
4.7 shows the two-dimensional projection of the QDA results when discriminating the 
samples based on tissue type. Less overlap is observed between the different groups and 
leave-one-out cross validation results in 934 out of 1009 samples being correctly classified, 
or a 93% accuracy. 
Once classified by cell type, additional directed partitioning techniques, detailed in 
Chapter 3, can be used to detect and diagnosis cancer for the different tissue types. Figure 
4.8 and Figure 4.9 shows the QDA results when discriminating breast, colon, and prostate 































Figure 4.6-Two-dimensional depictions of the QDA results when discriminating the 
tissue extracts based on tissue type and disease status (8 SLs by 6 tissue types / disease 
status, N = 1009). Ellipses represent 95% confidence intervals. 
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tissue samples based on disease status and metastatic potential, respectively. One may 
expect that, incorporating more sensors would increase the ability of the array to 
successfully distinguish components in a complex environment. However, this can also 
result in higher background noise and therefore decrease the accuracy of the model. This 
idea is similar to the law of diminishing returns where too much of something, even a good 
thing, can have has an adverse effect. For example, in Chapter 2, the development of a 
single analyte screen for the identification of prostate cancer selective SLs was discussed. 
However, when using this method, prostate selective SLs, rather than prostate cancer 
associated SLs, could be identified. If these SLs were identified and incorporated in the 
array, the accuracy of the array when discriminating based on disease status would decrease 
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Classification Accuracy = 93%
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Figure 4.7- Two-dimensional depictions of the QDA results when 
discriminating the tissue extracts b sed on tissue type (9 SLs by 3 tissue 
types, N = 1009). Ellipses represent 95% confidence intervals. 
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because the response would be biased for identifying differences in tissue type. By 
manipulating which SL for the analysis shown in Figure 4.7, the accuracy of the array 
should increase. By manipulating which SLs are included in the analysis, the accuracy of 
the model can be improved. SLs with the largest F-scores were included in the analysis 
since they contribute the most to the overall ability of the array to distinguish classes.  
 For these studies, data was collected for all 9 SLs however different combinations 
of SLs were used in the analysis. The breast tissue analysis, depicted by Figure 4.8, used 
a 4 SL array composed of SL 7, 1, 2, and 6 (ranked from largest to smallest F-score) 
whereas all other analysis utilized all 9 SLs in the results. SLs with the largest F-scores 
were included in the analysis since they contribute the most to the overall ability of the 
array to distinguish classes. F-scores are discussed in detail in chapter 2.  
Figure 4.8 depicts the QDA results when discriminating the tissue samples based 
on disease status. All the box and whisker plots have minimal to no overlap between the 
box plots and all analyses result in a p-value of <0.0001. Leave-one-out cross validation 






























































Figure 4.8- Depictions of the QDA results when discriminating breast, colon, and 
prostate cell lines extracts based on disease status (9 SLs by 2 statuses). The italicized 
numbers indicate the number of samples that were correctly classified out of the total 
sample population in the leave-one-out analysis. 
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Figure 4.9 show the two-dimensional projection of the QDA results when 
discriminating based on metastatic potential. In this analysis, 4 breast tissue samples were 
used: with 3 of the samples being human epidermal growth factor receptor 2 positive 
(HER2+) and the other sample being triple negative. Samples that are HER2+ express the 
human epidermal growth factor which promotes cancer cell growth.95 These samples were 
chosen to represent the lowly metastatic or non-invasive cancer types. In contrast, the triple 
negative sample does not express estrogen, progesterone and HER2+ receptors It is 
important to note that these types of cancer are commonly misdiagnosed as healthy because 
the cells resemble healthy basal cells. They are highly aggressive and deadly and therefore, 
this sample was chosen to represent the highly metastatic or invasive cancer types. Also, 
22 colon cell line samples were used: with 8 of the samples considered lowly metastatic 







































Figure 4.9- Depictions of the QDA results when discriminating breast, 
colon, and prostate cell lines extracts based on metastatic potential (9 SLs 
by 2 potentials). The italicized numbers indicate the number of samples 
that were correctly classified out of the total sample population in the 
leave-one-out analysis. 
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Finally, this analysis was not completed with prostate tissue extracts because all the 
samples had a Gleason score of 7. Pathologists grade prostate cancers using numbers from 
1 to 5 based on how much the cells in the cancerous tissue look like normal prostate tissue 
under the microscope. This is known as the Gleason system.96 Grades 1 and 2 are not used 
for biopsies, because most biopsy samples are grade 3 or higher. If the cancerous tissue 
looks much like normal prostate tissue, a grade of 1 is assigned and if cells and their growth 
patterns look very abnormal, it is assigned 5. Grades 2 through 4 have features in between 
these two extremes. Since prostate cancers often have areas with different grades, a grade 
is assigned to two areas that make up most of the cancer. These 2 grades are added to yield 
the Gleason score (also called the Gleason sum). The highest Gleason score can be 10. The 
first number assigned is the grade that is most common in the tumor. For example, the 
Gleason score written as 3+4=7, is understood as most of the tumor being grade 3 and some 
of it being grade 4, when they are added together, they make up for a Gleason sum of 7. 
Therefore, since all the samples were the same grade, an analysis comparing the different 
potentials of the samples could not be completed.  
Note that no overlap is observed between the box portion of the box-and-whisker 
plot and there is a p-value of 0.0001. Leave-one-out cross validation, for the breast tissue 
samples, results in 76 out of 78 samples being correctly classified, or a 97% accuracy. In 
comparison, 213 out of 217 colon tissue samples were correctly classified, or a 98% 
classification accuracy.  
The results described above show the adaptability of SL array when using primary 
human sources, e.g tissue samples. The array was able to detect breast cancer with an 
83.7% accuracy, colon cancer with an 82.8% accuracy and prostate cancer with an 89.3% 
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accuracy. While these results are lower than those obtained for the cell culture work, these 
results still are remarkable because the tissue samples did not undergo any purification 
methods to isolated only cancer associated membrane bound proteins and glycoproteins. 
Additionally, this decrease in accuracy may be caused by the use of matched pair. Matched 
pairs come from the same individual, therefore SL array may be detecting similarities in 
the samples that are not associated with cancer which will decrease the accuracy of the 
array. 
4.4 EVALUATING BLOOD SAMPLES FOR BREAST AND PROSTATE CANCER 
USING MULTIDIMENSIONAL ANALYSIS 
The above analyses highlighted the ability of the SL array to act as a cancer 
diagnostic when using tissue samples. However, am mentioned in Chapter 3, the focus of 
this project is to develop a liquid biopsy. Therefore, binding studies were completed using 
extracts isolated from human blood samples. Forty-three, ten, and seven blood samples 
were obtained as part of a university collaboration with Columbia Urological Associates 
(CUA), University of South Carolina (USC) Tissue Bank and USC medical school, 
respectively. The samples from CUA were drawn from individuals that had prostate cancer 
or some other urinary disease such as kidney stones. Blood samples obtained from the 
University of South Carolina Tissue Bank were drawn from individuals with breast cancer 
and samples from USC medical school were from individuals that did not have cancer. Of 
those with breast cancer, 3 were triple negative, 4 were luminal A positive, and 3 were 
luminal B positive. Luminal A breast cancers are low-grade, slow growing cancer that is 
positive for the estrogen and progesterone receptor.97 In comparison, Luminal B cancers 
are low-grade but faster growing cancer that is positive for the estrogen and progesterone 
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receptor. Triple negative cancers that are described in more detail above are high grade and 
fast growing. Since we did not have access to blood samples from individuals with colon 
cancer, we excluded colon cancer from this analysis.  
When a sample was obtained it was left to clot at room temperature before 
centrifuging and isolating the serum. The serum was concentrated using filter 
centrifugation, fluorescently tagged and binding studies with the SL library were assessed 
using fluorescence microscopy. Note that this isolation method used a 10 kDa cut-off filter 
thereby isolating any serum-based materials larger than 10 kDa, not just the proteins and 
glycoproteins associated with cancer.  
Figure 4.10 shows the two-dimensional projection of the QDA results when 
discriminating the blood sample extracts based on disease status combined with tissue type 
(4 classes, N=60). Note that in previous analyses each biological sample was measured 
multiple times to produce a minimum of 20 technical reps that were individually carried 
forward. In this analysis, however, these technical reps were combined such that each data 
point in the figure represents the average intensity for the biological sample not the 
response of each technical replicate. This was done to define each individual sample more 
clearly while also simplifying the graphical output.  
Although data was collected for all 9 SLs, only 5 SLs (SL 1, 2, 4, 5, and 9) were 
used in this analysis. We propose that since the normal prostate samples come from 
individuals that are suffering from other urological issues (e.g. kidney stones), they would 
74 
present differently than the blood samples drawn from the healthy patients at USC medical 
school. In comparison to Figure 4.6, minimal overlap is observed between the ellipses and 
therefore additional analyses were not carried out to discriminate tissue types. Note that 
the Discriminant 1 separates the sample according to tissue type while Discriminate 2 
separates the sample according to disease status. Ideally, the cancerous prostate and breast 
samples would align along this discriminant however this does not happen. This may be 
because most of the individuals that donated the normal prostate samples still had other 
urological issues or it may be because aggressive late-stage breast cancer (i.e. triple 
negative) can present as healthy samples. While some overlap is observed between the 
ellipses, leave-one-out cross validation results in a 54 out of 60 samples being correctly 






























Figure 4.10- Two-dimensional depictions of the QDA results when discriminating the 
blood extracts based on tissue type and disease status (5 SLs by 4 tissue types / disease 
status, N = 60). Each point represents the average intensity of the entire sample. Ellipses 
represent 95% confidence intervals.  
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Further studies focused on analyzing the individual cancer types with the SL array.  
Figure 4.11 shows the QDA results when discriminating the blood samples obtained from 
the USC tissue bank and medical school based on disease status. No overlap is observed 
between the boxes of the box-and-whisker plots and there is a p-value of <0.0001 
suggesting that there is a statistically significant difference between the data sets. Leave-
one-out cross validation results in 482 out of 525 samples being correctly classified, a 92% 
accuracy. It is worth highlighting that there was a false positive rate of ~4% with 8 out of 
the 226 healthy samples being misclassified as cancerous. Conversely, 35 out of the 299 
cancerous samples were misidentified as healthy, a ~12% false negative rate. While the 
false negative rate is higher than expected, it is worth noting that 27 out of the 35 
misclassified samples were from the same individual who suffered from Luminal B breast 




























Figure 4.11- Depictions of the QDA results when 
discriminating blood samples based on breast 
cancer status (9 SLs by 2 states). The italicized 
numbers indicate the number of samples that were 
correctly classified out of the total sample 
population in the leave-one-out analysis. 
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were misclassified. Therefore, further studies focused on identifying if the different breast 
cancer subtypes effected the ability of the array to detect cancer.   
Figure 4.12 depicts the two-dimensional projection of the QDA results when 
discriminating the blood samples based on breast cancer subtype. Note that most of the 
overlap is observed between the Luminal B subtype and the Luminal A or healthy subtype. 
The overlap with the Luminal A samples is expected because both cancer types Even with 
this overlap, 488 out of 525 samples were correctly classified, a 93% accuracy. For this 
analysis, 9 out of the 226 healthy samples were misclassified, or a 4% false positive rate, 
which is the same observed result when discriminating the data set based on disease status. 
However, only 15 out of the 299 cancerous samples were misclassified, or a 5% false 





























Figure 4.12- Two-dimensional depictions of the QDA results when discriminating the 
blood samples based on breast cancer subtype (9 SLs by 4 subtypes). 
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negative rate. By re-analyzing this data set under a different set of parameters the false 
negative rate was almost halved. Thereby highlighting the adaptability of cross-reactive 
arrays when using multi-dimensional analysis. Additionally, all the misclassified samples 
were from the sample individual that had misclassified 27 times in the previous analysis.  
Our final study focused on discriminating the 43 samples obtained from CUA based 
on the prostate cancer status (Figure 4.13). Less information was known about the 
individuals who donated samples at CUA so we could only analyze this data set based on 
disease status. For this analysis, SL 1-9 and 11 were incorporated into the array since SL 
11 had shown the most promise at detecting prostate cancer, discussed in Chapter 3. No 





























Figure 4.13- Depictions of the QDA results when discriminating 
blood samples based on prostate cancer status (10 SLs by 2 
states). The italicized numbers indicate the number of samples 
that were correctly classified out of the total sample population 
in the leave-one-out analysis. 
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of <0.0001 suggesting that there is a statistically significant difference between the data 
sets. Leave-one-out cross validation results in 40 out of 43 samples being correctly 
classified, a 93% accuracy. Significantly, all the cancer samples were correctly classified 
and only 3 of the healthy samples were misclassified. Therefore, there was a false positive 
rate of 24% which is an improvement to the PSA blood test which has a false positive rate 
of 75%. Significantly, none of the cancerous samples were misidentified affording a 0% 
false negative rate. While these are exceptional results, more samples and information 
about the samples needs to be provided before further conclusions can be drawn.  
4.5 CONCLUSION 
This chapter aimed to test the utility of the SL array when (A) detecting cancer from 
multiple sites and (B) using primary human derived samples, i.e. tissue and blood. The 
above analyses showed that the array was able to discriminate cell lines, tissue and blood 
extracts based on disease status with a 94%, 84%, and 90% classification accuracy, 
respectively.  From these analyses, we have learned that the SL array has the potential to 
serve as a cancer screening method. However, the blood analysis showed that having pre-
existing conditions, such as kidney stones, causes a difference in response from healthy 
samples. This result is not surprising because aberrant glycosylation occurs during a variety 
of different diseases, such as inflammation and auto-immune disease, not just cancer.ref 
Therefore, before this method can become a screening method, a database needs to be 
generated using information from individuals with a variety of different condition.  
Additionally, the blood analysis suggest that a more developed database is needed 
before the method can be used to subtype the different cancer types. While the array was 
able to discriminate between cancerous and healthy samples, major overlap is seen when 
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discriminating the samples based on breast subtype (Figure 4.12). One possible solution, 
is to use the dual dye competitive method, described in Chapter 2, to identify SLs that are 
selective for specific breast cancer subtypes. Interestingly, subtype specific SLs can be 
used for more then just our diagnostic method. For example, if we were to identify a SL 
that was selective for triple negative breast cancer, we could use glycomics and proteomics 
to identify a biomarker for this type of cancer. Even with these changes, this method 
currently shows promise as a diagnostic.  
4.6 FUTURE WORK 
As mentioned above, future work will focus on developing a database that future 
samples can be compared to. Note that more technical and biological replicates of the 
samples will be needed to confirm that the results discussed above are reproducible and 
accurate. For example, three replicates of data have been obtained from that blood samples 
collected from CUA. Additionally, data needs to be collected from more individuals 
diagnosed with prostate and breast cancer as well as other cancer types, such as colon, 
ovarian, or lung cancer. When blood is drawn, the blood has been circulated throughout 
the entire body and therefore is not specific to an organ. Therefore, we need to incorporate 
a diverse dataset from individuals diagnosed with different cancer types.  
To collect all the necessary data for the dataset, we need to streamline data 
collection by using a high throughput method, such as flow cytometry. While using 
fluorescent microscopy has obtained remarkable results, data collection is a labor-intensive 
process. Using this method is not realistic for the number of samples that need to be run to 
validate the utility of the SL array as a diagnostic tool. Therefore, the Lavigne lab has 
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started to use flow cytometry and promising results have been obtained. Furthermore, 
robotics can be used to streamline sample preparation.  
Finally, we would have to expand on the future work discussed in Chapter 3, which 
details using antibodies or mass spectrometry to identify what the SLs are binding. To 
receive FDA approval, one needs a detailed understanding of how the diagnostic works. 
Therefore, we cannot just say that the array binds cross-reactively and instead will need to 
be able to identify what exactly we are binding. Overall, this method shows promise as a 
potential diagnostic tool but more work needs to be completed before we can call it a 
diagnostic method.  
4.7 EXPERIMENTAL METHODS 
General Methods. All chemicals were purchased from Millipore Sigma or Thermo 
Fisher Scientific and used without further purification.  TentaGel resin (Cat. No. MB-300-
002; loading level 0.25-0.3 mmol/g) was purchased from Rapp Polymere.  Cell growth 
media and fetal bovine serum was purchased from VWR International, LLC (West Chester, 
PA).  BCA protein quantification kits were purchased from Thermo Fisher Scientific.  
Amicon 3kDa centrifuge tubes and the Sialic Acid Quantitation Kit were purchased from 
Millipore Sigma.  
Synthesis of SL Library.  Standard Fmoc / HBTU chemistry was used to attach a 
peptide backbone to the TentaGel resin. The peptides in this library have the general 
sequence Ac-R-X-D*-X-X-X-D*-X-B-B-R-M-resin where B denotes beta-alanine, D* 
denotes diamino butanoic acid functionalized with 4-formylphenyl boronic acid, and X 
denotes a random amino acid.  250 mg of resin beads were weighed out and soaked in DMF 
for 10 minutes. 8 equivalents of methionine and HBTU were dissolved in 10 mL of 5% N-
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methylmorpholine / DMF.  The solution was left at room temperature for 10 minutes before 
mixing with the resin.  After tumbling for 1 hour, the beads were washed with DMF and 
methanol.  A ninhydrin tests were performed to determine if the amino acids had coupled.  
The Fmoc group was removed by tumbling the beads in 10 mL 20% piperdine in DMF for 
30 minutes.  This process was repeated with arginine and then two β-alanines.  The random 
amino acid, X, was coupled to the beads using the split-and-pool method.  Briefly, the 
beads were split into 12 different reaction vessels that each contain a different activated 
amino acid.  After coupling, the beads were combined back into one vessel and deprotected 
using 20% piperdine in DMF.  Since the next position is fixed with D*, the beads are 
coupled to the amino acid and deprotected in the same vessel.  The next 6 amino acids are 
coupled depending on the fixed or random position of that amino acid.  Once all the amino 
acids were coupled, the end of the peptide strand is acylated by tumbling the resin in 10 
mL of 90% dichloromethane, 5% acetic anhydride, and 5% pyridine.  The ivDde protecting 
group of D* was removed by using 10 mL of a 5% hydrazine / DMF solution.   
Incorporation of Phenyl Boronic Acid.  2-Formylphenyl boronic acid (8eq) was 
dissolved in a mixture of 10% methanol in DMF.  The resin beads, along with activated 
3Ǻ molecular sieves, were added into the solution and tumbled at 37ºC overnight.  NaBH4 
(8 eq) was added before and the reaction was left uncapped to allow H2 gas to escape for 
45-minutes.  The resin was left to tumble at 37ºC for 4-hours.  The resin was then separated 
from the molecular sieves, based on density, using dichloromethane.  This was followed 
by washing the beads with copious amounts of DMF and methanol. 
MS/MS Analysis.  To verify that the PS3 coupled the correct sequence onto the resin 
MS/MS analysis was used. The peptide was then cleaved from the resin, the beads were 
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treated with 50 μl of 40 mg/ml cyanogen bromide (CNBr) in 0.1 M HCl for 16 hours in the 
dark.  The beads were removed from the solution and the excess CNBR, TFA, and water 
were removed under reduced pressure by using an AES1010 SpeedVac system.  The 
cleaved peptides were re-dissolved in 10 μl of 0.1% TFA in water.  A solution of 50:50:0.1 
acetonitrile/water/TFA was saturated with α-cyano-4-hydroxycinniamic acid (CHCA).  On 
a MALDI plate, 1 μl of this matrix containing solution was mixed with 2 μl of the cleaved 
SL solution and dried under ambient conditions.  Samples were then analyzed by MALDI-
TOF/MS and MS/MS techniques. 
Removal of Acid Laible Groups. Molecular sieves were removed, and the beads 
were transferred to a Flacon tube.  After the boronic acid moiety was coupled, 10mL of 
95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane (9.5 ml, 250 μL, 
250 μL resp.) was added and the resin was tumbled for 1 hour to deprotect the acid-labile 
protecting groups.  The TFA wash was repeated one more time.  The resin was then washed 
with DMF and methanol.  SLs were tumbled with PBS without glycerol (pH 7.25) twice 
for 10 minutes before future use. 
Microscopy. All fluorescent images were taken using a Leica MZ 16F microscope 
equipped with a GFP3 filter (excitation 450-490 nm; emission filter 500-550 nm), DSR 
filter (excitation 510-560 nm; emission filter 590-650 nm), and a QImaging 
MicroPublisher 5.0 RTV digital camera.  Images were analyzed using a MATLAB 
algorithum which provided fluorescent intensities.  
Binding Studies with Fluorescent-labeled Membrane Extracts. Approximately 2 
mg of SL was rinsed in PBS twice and then pre-incubated with 1% BSA in PBS with 10% 
glycerol for 15 minutes. This pre-incubation was to reduce the nonspecific binding between 
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the SL and proteins.  The 1% BSA in PBS with 10% glycerol solution was then removed 
from the beads and 1 mL of a 0.0002 mg/mL solution 45 of the fluorescently labeled colon 
membrane extract in PBS was incubated with the beads for 6 hours at room temperature 
with gentle shaking.  After incubation, the beads were rinsed with PBS three times, imaged 
with a fluorescent microscope, Leica MZ 16F, and analyzed by Matlab R2012a.  The output 
was analyzed by linear discriminant analysis using SYSTAT 11.00.01. 
Cell Culture. VWR supplied all the supplements and media needed for cell culture.  
RWPE-1, WPE1- NA22 and WPE1-NB14 cells were grown in Keratinocyte Serum Free 
Media (K-SFM) supplemented with human recombinant epidermal growth factor (rhEGF) 
and bovine pituitary extract (BPR).  PC3, LNCaP, HCT 116 and LoVo cells were grown 
in RPMI 1640 media with 10% feline bovine serum (FBS).  DU145 CCD-841-CON and 
HT29 cells were grown in Eagle’s Minimum Essential Medium Cells supplemented with 
10% v/v of FBS and 1% antibiotics / anti-mycotic were passaged upon 75 % confluence in 
T75 Flasks.  
Extracting Membrane Samples. The Qiagen Plasma Membrane Protein Kit was 
used to extract plasma membrane proteins and glycoproteins. This kit isolates all 
membrane bound proteins not only cancer associated markers. The extract was spun into 
carbonate buffer pH 9.8 and a BCA assay was performed to obtain the concentration of the 
extract. 
Extracting Proteins from Tissue Samples. Samples arrived frozen from the Core 
Facility at the University of South Carolina. The frozen tissue was sliced with a scalpel in 
a -20°C microtome before being immediately placed in a 15-mL falcon tube containing 
5mL of neutral buffered formaldehyde (NBF) at room temperature. The tissue samples 
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were then pulverized in liquid nitrogen using a mortar and pestle. The mortar and pestle 
were pre-chilled by pouring in liquid nitrogen and allowing it to evaporate. The tissue was 
place along with a little amount of nitrogen was transferred to the mortar and pestle. Note 
that the tissue must remain in nitrogen at all the times. After pulverizing, the tissue was 
transferred into an Eppendorf containing 1mL of cold lysis buffer with protease inhibitors. 
The crushed sample was passed through a 16 G needle several times, to break any larger 
chunks of tissues and to create a slurry. The slurry was centrifuged using 4°C centrifuge 
for 20 minutes before removing the supernatant. The proteins and glycoproteins were 
isolated from the supernatant using a Qiagen Membrane Extraction kit. 
Extracting Proteins from Blood Samples Blood samples were received and instantly 
inverted 8 times and left to clot at room temperature for 30 mins. After clotting, the blood 
tubes were centrifuged at 1300 rpm for 10 minutes. 1000 µL aliquots of the supernatant 
were left in a -80°C until later use.  
Fluorescently Labeling Protein Samples. 28 µg of FITC (71.9 nmol) in DMF was 
added to the isolated membrane and secreted protein samples. The solution was incubated 
at 37°C and tumbled for 1 hr before being transferred to an Amicon Pro Centrifugal Filter 
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SYSTAT OUTPUT FOR CHAPTER 2
 
This output shows the statistical output from Systat. Similar outputs were obtained for 
chapter 3 and 4 but we excluded because of space.  
Validation of SL Binding:  Discrimination of RWPE-1 and PC3 (SL10) 
In this analysis, we used SL 10 to classify the normal prostate cell line, RWPE-1, and the 
highly metastatic prostate cell lines, PC3.  This analysis looked at the SL hits ability to 
detect changes in glycosylation between cell lines of differing disease status.  RWPE-1 
and PC3 were chosen in this analysis because they were used in the initial single analyte 







SL 10 0.609 0.571 











Lambda = 0.9663 
 
df =   1   1  35 
  
Approx. 












SL 10 1.22 1.000 
 
Classification matrix (cases in row categories classified into columns) 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 7 12 63 
Total 16 21 57 
 
Jackknifed classification matrix 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 7 12 63 










   
Cumulative proportion of total dispersion 
1.000 
   
Wilks' lambda 
lambda  =   0.966 
    
Approx.F=   1.220 
 




trace  =   0.034 
    
Approx.F=   1.220 
 




trace  =   0.035 
    
Approx.F=   1.220 
 
df=  1,   35 
p-tail 
=0.28 




SL 10 9.755 
Canonical discriminant functions -- standardized by within variances 
 
1 











Validation of SL Binding:  Discrimination of RWPE-1 and PC3 (SL11) 
For this study, we used SL 11 to classify the RWPE-1 and PC3.  RWPE-1 and PC3 were 
chosen in this analysis because they were used in the two-colored dual analyte competitive 







SL 11 0.725 0.366 





RWPE-1 614.471 0 
Wilks' lambda 
Lambda = 0.0539 
 
df =   1   1  35 
  
Approx. 









CONSTANT -135.918 -35.031 






SL 11 614.47 1.0000 
 
Classification matrix (cases in row categories classified into columns) 
 
PC3 RWPE-1 %correct 
PC3 18 0 100 
RWPE-1 0 19 100 
Total 18 19 100 
 
Jackknifed classification matrix 
 
PC3 RWPE-1 %correct 
PC3 18 0 100 
RWPE-1 0 19 100 











Cumulative proportion of total dispersion 
1.000 
   
Wilks' lambda 
lambda  =   0.054 
    
Approx.F=   614.471 df=  1,   35 p-tail =  0 
Pillai's trace 
trace  =   0.946 
    
Approx.F=   614.471 df=  1,   35 p-tail =  0 
Lawley-Hotelling trace 
trace  =   17.556 
    
Approx.F=   614.471 df=  1,   35 p-tail =  0 




SL 11 22.680 
Canonical discriminant functions -- standardized by within variances 
 
1 
SL 11 1.000 











Validation of SL Binding:  Discrimination of RWPE-1 and PC3 (SL12) 
In this analysis, we used SL 12 to classify RWPE-1, and  PC3 because they were used in 







SL 12 0.739 0714 





RWPE-1 0.611 0 
Wilks' lambda 
Lambda = 0.9828 
 













CONSTANT -29.716 -27.737 
SL 12 78.425 75.777 










SL 12 0.61 1.0000 
Classification matrix (cases in row categories classified into columns) 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 8 11 58 
Total 17 20 54 
Jackknifed classification matrix 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 8 11 58 






   
Cumulative proportion of total dispersion 
1.000 
   
Wilks' lambda 
lambda  =   0.983 
    
Approx.F=   0.611 
 






trace  =   0.017 
    
Approx.F=   0.611 
 
df=  1,   35 p-tail =0.44 
Lawley-Hotelling trace 
trace  =   0.017 
    
Approx.F=   0.611 
 
df=  1,   35 p-tail =0.44 




SL 12 10.298 
Canonical discriminant functions -- standardized by within variances 
 
1 
SL 12 1.000 






Validation of SL Binding:  Discrimination of RWPE-1 and PC3 (SL13) 
In this study, RWPE-1 and PC3 were classified based on the response to SL 13. This SL 












SL 13 0.822 0.790 





RWPE-1 1.048 0 
Wilks' lambda 
Lambda = 0.9709 
 
df =   1   1  35 
  
Approx. 




CONSTANT -37.558 -34.671 






SL 13 1.05 1.0000 
Classification matrix (cases in row categories classified into columns) 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 8 11 58 






Jackknifed classification matrix 
 
PC3 RWPE-1 %correct 
PC3 9 9 50 
RWPE-1 9 10 53 






   
Cumulative proportion of total dispersion 
1.000 
   
Wilks' lambda 
lambda  =   0.971 
    
Approx.F=   1.048 df=  1,   35 p-tail =0.31 
Pillai's trace 
trace  =   0.029 
    
Approx.F=   1.048 df=  1,   35 p-tail =0.31 
Lawley-Hotelling trace 
trace  =   0.030 
    
Approx.F=   1.048 df=  1,   35 p-tail =0.31 








SL 13 10.442 
Canonical discriminant functions -- standardized by within variances 
 
1 
SL 13 1.000 






Validation of SL Binding:  Discrimination of RWPE-1 and PC3 (SL14) 
In this analysis, we used SL 14 to classify RWPE-1, and PC3.  SL 14 was identified from 







SL 14 0.518 0.442 













Lambda = 0.3313 
 
df =   1   1  35 
  
Approx. 




CONSTANT -176.270 -128.238 






SL 14 70.64 1.0000 
Classification matrix (cases in row categories classified into columns) 
 
PC3 RWPE-1 %correct 
PC3 16 2 89 
RWPE-1 2 17 89 
Total 18 19 89 
Jackknifed classification matrix 
 
PC3 RWPE-1 %correct 
PC3 16 2 89 
RWPE-1 2 17 89 











   
Cumulative proportion of total dispersion 
1.000 
   
Wilks' lambda 
lambda  =   0.331 
    
Approx.F=   70.638 df=  1,   35 p-tail =  0 
Pillai's trace 
trace  =   0.669 
    
Approx.F=   70.638 df=  1,   35 p-tail =  0 
Lawley-Hotelling trace 
trace  =   2.018 
    
Approx.F=   70.638 df=  1,   35 p-tail =  0 




SL 14 36.144 
Canonical discriminant functions -- standardized by within variances 
 
1 
SL 43 1.000 









Validation of SL Binding: Discrimination of 6 Prostate Cell Lines  
In this analysis, we used an array composed of SL 10-14 to classify 6 prostate cell lines.  
This analysis looked at the SL arrays ability to detect changes in glycosylation between the 
different cell lines. This analysis also identified which SLs had the largest contribution on 
classification. 
Group Frequencies 





20 19 18 19 20 20 
Group means 
 





SL 10 0.489 0.644 0.609 0.571 0.725 0.807 
SL 11 0.560 0.731 0.725 0.366 0.581 0.772 
SL 12 0.532 0.719 0.739 0.714 0.766 0.795 
SL 13 0.730 0.883 0.822 0.790 0.859 0.894 
SL 14 0.451 0.493 0.518 0.442 0.401 0.428 
Wilks' lambda 
Lambda = 0.0118 df =  5  5  110   
Approx. F= 36.3698 df =  25  395    prob =  0 
Classification functions 










SL 10 61.49 82.809 78.95 75.16 95.81 106.28 
SL 11 264.83 344.66 338.96 180.32 279.38 364.15 
SL 12 75.48 102.56 105.78 103.20 111.27 115.66 
SL 13 92.15 113.46 105.29 88.66 104.85 115.19 
SL 14 454.07 492.11 520.89 448.04 396.69 419.76 
 
Included   
Variable F-to-remove Tolerance 
SL 10 10.54 0.981161 
SL 11 125.08 0.967303 
SL 12 13.21 0.983607 
SL 13 2.75 0.952073 
SL 14 23.83 0.995105 
 
Classification matrix (cases in row categories classified into columns) 






DU145 18 0 0 2 0 0 90 
LNCaP 0 13 6 0 0 0 68 
PC3 0 5 13 0 0 0 72 
RWPE-1 0 0 0 18 1 0 95 
WPE1-
NA22 
0 0 0 0 
20 0 100 
WPE1-
NB14 
0 1 0 0 





Total 18 19 19 20 21 19 87 
Jackknifed classification matrix 
 





DU145 16 1 0 2 1 0 80 
LNCaP 0 12 6 0 0 1 63 
PC3 0 7 11 0 0 0 61 
RWPE-1 0 0 0 18 1 0 95 
WPE1-
NA22 
0 0 0 




0 1 0 
0 0 19 
95 
Total 16 21 17 20 22 20 83 
Eigenvalues 
10.339 2.883 0.838 0.040 0.005 
 
Canonical correlations 
0.955 0.862 0.675 0.196 0.068 
Cumulative proportion of total dispersion 
0.733 0.937 0.997 1.000 1.000 
Wilks' lambda 
Lambda = 0.012     
Approx.F= 36.395 df  =  25,   395 p-tail =   0 
Pillai's trace 





Approx.F= 16.642  df  =  25,   550 p-tail =   0 
Lawley-Hotelling trace 
trace  =   14.104     
Approx.F= 58.899  df  =  25,   522 p-tail =   0 
Canonical discriminant functions 
 1 2 3 4 5 
Constant -19.168 2.476 -14.169 4.002 -3.391 
SL 10 2.840 6.940 1.782 1.949 8.510 
SL 11 19.742 -3.644 -5.465 1.169 -2.985 
SL 12 1.926 5.511 7.983 3.556 -5.868 
SL 13 3.018 1.344 0.768 -10.517 -1.245 
SL 14 2.626 -21.337 22.261 0.484 10.977 
 
 
Canonical discriminant functions -- standardized by within variances 
 1 2 3 4 5 
SL 10 0.246 0.602 0.155 0.169 0.738 
SL 11 0.954 -0.176 -0.264 0.056 -0.144 
SL 12 0.161 0.462 0.669 0.298 -0.492 
SL 13 0.278 0.124 0.071 -0.969 -0.115 








Canonical scores of group means 
 1 2 3 4 5 
DU145 -2.306 -1.872 -1.519 0.045 0.009 
LNCaP 2.432 -1.100 0.384 -0.384 0.003 
PC3 2.142 -1.823 1.028 0.270 -0.048 








-0.379 0.111 0.090 
Enhanced cancer cell discrimination: Directed Partitioning and Data Reduction 
Methods (SL 10-14: Potential) 
To further probe the ability of the SL array we used directed partitioning to discriminate 
the 6 prostate cell lines based on metastatic potential.  This analysis attempted to find 
similarities in glycosylation between cell lines of the same disease status while finding 
differences between cell lines of carrying status. This analysis also identified which SLs 























SL 10 0.578 0.766 0.571 
SL 11 0.669 0.677 0.366 
SL 12 0.660 0.781 0.714 
SL 13 0.810 0.877 0.790 
SL 14 0.486 0.415 0.442 









0.000   
Cancerous/ 
Lowly 
56.566 0.000  
Healthy 46.449 45.557 0.000 
Wilks' lambda 
Lambda = 0.0917  df =  5   2   113   








SL 10 19.93 0.773198 





SL 12 14.88 0.753423 
SL 13 0.34 0.846978 
SL 14 45.94 0.759826 
 









55 0 2 96 
Cancerous/ 
Lowly 
0 40 0 100 
Healthy 0 1 18 95 
Total 55 41 20 97 
 









53 2 2 93 
Cancerous/ 
Lowly 
0 40 0 100 
Healthy 0 1 18 95 










Cumulative proportion of total dispersion 
0.562 1.000 
Wilks' lambda 
Lambda = 0.092     
Approx.F= 50.180  df  =  10,   218 p-tail =   0 
 
Pillai's trace 
trace  =   1.392     
Approx.F= 50.366  df  =  10,   220 p-tail =   0 
 
Lawley-Hotelling trace 
trace  =   4.629     
Approx.F= 49.989  df  =  10,   216 p-tail =   0 
Canonical discriminant functions 
 1 2 
Constant 3.444 1.251 
SL 10 6.844 0.530 
SL 11 -2.370 -12.756 
SL 12 4.858 3.452 
SL 13 0.597 -0.817 






Canonical discriminant functions -- standardized by within variances 
 1 2 
SL 10 0.690 0.053 
SL 11 -0.221 -1.190 
SL 12 0.518 0.368 
SL 13 0.061 -0.083 
SL 14 -0.840 0.372 
 
Canonical scores of group means 







Healthy 0.403 3.155 
 
Classification matrix (cases in row categories classified into columns) 






DU145 18 0 0 2 0 0 90 
LNCaP 0 13 6 0 0 0 68 
PC3 0 5 13 0 0 0 72 
RWPE-1 0 0 0 18 1 0 95 
WPE1-
NA22 
0 0 0 0 







0 1 0 0 
0 19 95 
Total 18 19 19 20 21 19 87 
 
Jackknifed classification matrix 
 





DU145 16 1 0 2 1 0 80 
LNCaP 0 12 6 0 0 1 63 
PC3 0 7 11 0 0 0 61 
RWPE-1 0 0 0 18 1 0 95 
WPE1-
NA22 
0 0 0 




0 1 0 
0 0 19 
95 
Total 16 21 17 20 22 20 83 
 
Eigenvalues 
10.339 2.883 0.838 0.040 0.005 
 
Canonical correlations 
0.955 0.862 0.675 0.196 0.068 
 
Cumulative proportion of total dispersion 







Lambda = 0.012     
Approx.F= 36.395 df  =  25,   395 p-tail =   0 
 
Pillai's trace 
trace  =   2.153     
Approx.F= 16.642 df  =  25,   550 p-tail =   0 
 
Lawley-Hotelling trace 
trace  =   14.104     
Approx.F= 58.899 df  =  25,   522 p-tail =   0 
 
Canonical discriminant functions 
 1 2 3 4 5 
Constant -19.168 2.476 -14.169 4.002 -3.391 
SL 10 2.840 6.940 1.782 1.949 8.510 
SL 11 19.742 -3.644 -5.465 1.169 -2.985 
SL 12 1.926 5.511 7.983 3.556 -5.868 
SL 13 3.018 1.344 0.768 -10.517 -1.245 
SL 14 2.626 -21.337 22.261 0.484 10.977 
 





 1 2 3 4 5 
SL 10 0.246 0.602 0.155 0.169 0.738 
SL 11 0.954 -0.176 -0.264 0.056 -0.144 
SL 12 0.161 0.462 0.669 0.298 -0.492 
SL 13 0.278 0.124 0.071 -0.969 -0.115 
SL 14 0.080 -0.651 0.680 0.015 0.335 
 
Canonical scores of group means 
 1 2 3 4 5 
DU145 -2.306 -1.872 -1.519 0.045 0.009 
LNCaP 2.432 -1.100 0.384 -0.384 0.003 
PC3 2.142 -1.823 1.028 0.270 -0.048 

















EDMAN DEGRATION SEQUENCES 
The following figures show the Edman Degradation chromatograms received from Tufts 
University. All of the peptides have the same general sequence, R-X-D*-X-X-X-D*-X-
BBRM, where X represents a random amino acid, D* represent diaminobutyric acid, and 
B represent β–Ala. MRBB is a conserved sequence, so the spectra are not shown. The N-










Figure B.1- Edman Sequence Results for SL10 Amino Acid 1  









Figure B.2- Edman Sequence Results for SL10 Amino Acid 2 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. Leucine was present in the first randomized 









Figure B.3- Edman Sequence Results for SL10 Amino Acid 3The sequence of SL10 is R-L-D*-A-R-S-









Figure B.4- Edman Sequence Results for SL10 Amino Acid 4 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. Alanine was present in the second randomized 









Figure B.5- Edman Sequence Results for SL10 Amino Acid 5 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. Arginine was present in the third randomized 









Figure B.6- Edman Sequence Results for SL10 Amino Acid 6 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. Serine was present in the fourth randomized 









Figure B.7- Edman Sequence Results for SL10 Amino Acid 7 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.8- Edman Sequence Results for SL10 Amino Acid 8 
The sequence of SL10 is R-L-D*-A-R-S-D*-G-B-B-R-M. Glycine was present in the fifth randomized 









Figure B.9-  Edman Sequence Results for SL11 Amino Acid 1 









Figure B.10- Edman Sequence Results for SL11 Amino Acid 2 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Leucine was present in the first randomized 









Figure B.11- Edman Sequence Results for SL11 Amino Acid 3 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.12- Edman Sequence Results for SL11 Amino Acid 4 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Tyrosine was present in the second 









Figure B.13- Edman Sequence Results for SL11 Amino Acid 5 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Leucine was present in the third randomized 









Figure B.14- Edman Sequence Results for SL11 Amino Acid 6 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Threonine was present in the fourth 









Figure B.15- Edman Sequence Results for SL11 Amino Acid 7 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.16- Edman Sequence Results for SL11 Amino Acid 8 
The sequence of SL11 is R-L-D*-Y-L-T-D*-R-B-B-R-M. Arginine was present in the fifth randomized 









Figure B.17- Edman Sequence Results for SL12 Amino Acid 1 









Figure B.18- Edman Sequence Results for SL12 Amino Acid 2 
The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. Leucine was present in the first randomized 









Figure B.19- Edman Sequence Results for SL12 Amino Acid 3 
The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.20- Edman Sequence Results for SL12 Amino Acid 4 
The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. Glycine was present in the second randomized 









Figure B.21- Edman Sequence Results for SL12 Amino Acid 5 










Figure B.22- Edman Sequence Results for SL12 Amino Acid 6 










Figure B.23- Edman Sequence Results for SL12 Amino Acid 7 
The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.24- Edman Sequence Results for SL12 Amino Acid 8 
The sequence of SL12 is R-L-D*-G-F-Y-D*-Q-B-B-R-M. Glutamine was present in the fifth randomized 









Figure B.25- Edman Sequence Results for SL13 Amino Acid 1 









Figure B.26- Edman Sequence Results for SL13 Amino Acid 2 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. Threonine was present in the first randomized 









Figure B.27- Edman Sequence Results for SL13 Amino Acid 3 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.28- Edman Sequence Results for SL13 Amino Acid 4 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. Glycine was present in the second randomized 









Figure B.29- Edman Sequence Results for SL13 Amino Acid 5 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. Leucine was present in the third randomized 









Figure B.30- Edman Sequence Results for SL13 Amino Acid 6 










Figure B.31- Edman Sequence Results for SL13 Amino Acid 7 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.32- Edman Sequence Results for SL13 Amino Acid 8 
The sequence of SL13 is R-T-D*-G-L-A-D*-V-B-B-R-M. Valine was present in the fifth randomized 









Figure B.33- Edman Sequence Results for SL14 Amino Acid 1 










Figure B.34- Edman Sequence Results for SL14 Amino Acid 2 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. Tyrosine was present in the first randomized 









Figure B.35- Edman Sequence Results for SL14 Amino Acid 3 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. D* is a fixed position in the library and is not 









Figure B.36- Edman Sequence Results for SL14 Amino Acid 4 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. Arginine was present in the second 









Figure B.37- Edman Sequence Results for SL14 Amino Acid 5 










Figure B.38- Edman Sequence Results for SL14 Amino Acid 6 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. Serine was present in the fourth randomized 







 Figure B.39- Edman Sequence Results for SL14 Amino Acid 7 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. D* is a fixed position in the library and is not 







Figure B.40- Edman Sequence Results for SL14 Amino Acid 8 
The sequence of SL14 is R-Y-D*-R-A-S-D*-V-B-B-R-M. D* is a fixed position in the library and is not 
recognized by Edman Degradation. 
